

Curriculum Vitae Europass



PERSONAL INFORMATION

Name **TRIFIRO GIANLUCA**
 Address Department of Diagnostics and Public Health – Section of Pharmacology – University of Verona - Policlinico Universitario “G.B. Rossi” - Piazzale L. Scuro, 10 - 37134 Verona - Italy
 E-mail gianluca.trifiro@univr.it
 Nationality Italian

Work experience

Date	From 1st January 2022 -
Occupation or position held	Clinical Pharmacologist at the clinical pharmacology unit of Verona academic hospital
Main activities and responsibilities	Support of the activities concerning the Veneto regional center of Pharmacovigilance;
Name and address of employer	Unità Operativa Semplice Farmacologia Clinica -Azienda Ospedaliera Universitaria Integrata di Verona - Policlinico Universitario “G.B. Rossi” - Piazzale L. Scuro, 10 - 37134 Verona, Italy
Name and address of employer	Department of Diagnostics and Public Health - University of Verona, Policlinico Universitario “G.B. Rossi” - Piazzale L. Scuro, 10 - 37134 Verona, Italy
Date	From 1 st October 2020 -
Occupation or position held	Full Professor of Pharmacology
Main activities and responsibilities	Teaching - Research – Clinical activities
Name and address of employer	Department of Diagnostics and Public Health– University of Verona - Policlinico Universitario “G.B. Rossi” - Piazzale L. Scuro, 10 - 37134 Verona - Italy
Date	From 30th December 2017 to 30 th September 2020
Occupation or position held	Associate Professor of Pharmacology
Main activities and responsibilities	Teaching - Research – Health activities
Name and address of employer	Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina - Policlinico Universitario Messina “G. Martino” Via Consolare Valeria – Gazzi – Messina, Italy
Date	From 2nd September 2016 -
Lavoro o posizione ricoperti	Clinical Pharmacologist at the Phase I Clinical trial Unit of Department of Pediatric Onco-hematology and Transfusional Medicine of Pediatric Hospital of Bambino Gesù - Rome
Principali attività e responsabilità	Pharmacovigilance of clinical studies
Nome e indirizzo del datore di lavoro	Department of Pediatric Onco-hematology and Transfusional Medicine of Pediatric Hospital of Bambino Gesù - Piazza di Sant'Onofrio, 4 · 06 68591 Rome
Date	From 11th July 2012 – 1st February 2020

Occupation or position held	External consultant of the Scientific Secretariat of the Pharmacovigilance office of the Italian Drug Agency
Main activities and responsibilities	Consulting support about all the activities related to the pharmacovigilance office
Name and address of employer	Italian Drug Agency, Via del Tritone 181, Rome, Italy
Date	From 11 June 2012 to 30th September 2020
Occupation or position held	Clinical Pharmacologist
Main activities and responsibilities	Support of the activities concerning the Sicilian regional center of Pharmacovigilance; Drug Information Center; Monitoring of drug prescribing behavior
Name and address of employer	Unità Operativa Semplice Dipartimentale Farmacologia Clinica -Azienda Ospedaliera Universitaria "G. Martino" - Via Consolare Valeria – Gazzi – Messina, Italy
Type of business or sector	Health
Date	From 31st March 2011 to 29th December 2017
Occupation or position held	Assistant Professor of Pharmacology with tenure track (Associate Professor starting from 31 December 2017)
Main activities and responsibilities	Teaching - Research – Health activities
Name and address of employer	Department of Clinical and Experimental Medicine, University of Messina, Policlinico Universitario Messina "G. Martino" Via Consolare Valeria – Gazzi – Messina, Italy
Date	From 1st February 2010 -
Occupation or position held	Assistant Professor in Pharmacoepidemiology (Honorary position since 31 March 2011)
Main activities and responsibilities	Teaching - Research
Name and address of employer	Department of Medical Informatics – Erasmus University Medical Center, Dr. Molewaterplein 3000DR Rotterdam, Netherlands
Date	From 1st February 2009 to 1st February 2010
Occupation or position held	PostDoc in Pharmacoepidemiology
Main activities and responsibilities	Research
Name and address of employer	Department of Medical Informatics – Erasmus University Medical Center, Dr. Molewaterplein 3000DR Rotterdam, Netherlands
Date	From 13 th November 2006 to 1st February 2009
Occupation or position held	Research fellowship
Main activities and responsibilities	Research in pharmacovigilance and pharmacoepidemiology of psychotropic drugs
Name and address of employer	Laboratorio di Farmacovigilanza ed Epidemiologia Clinica relative ad uso, rischi e benefici dei farmaci psicotropi" - IRCCS Centro Neurolesi Bonino Pulejo – Messina, Italy
Date	From 1st January 2006 -
Occupation or position held	Consultant in pharmacoepidemiology
Main activities and responsibilities	Coordination of monitoring of prescribing behavior (audit-feedback) of specialists and GPs operating in the catchment area of the Local Health Unit of Caserta through analysis of claims and general practice databases
Name and address of employer	Local Health Unit of Caserta, Italy

Education and training

Date	22nd March 2010
Title of qualification awarded	Dottorato di Ricerca in Medicina Sperimentale
Principal subjects/occupational skills covered	Research in the field of pharmacoepidemiology, pharmacovigilance and, more in general, clinical pharmacology
Name and type of organization providing education and training	Department of Clinical and Experimental Medicine, University of Messina, Messina - Italy
Level in national classification (if appropriate)	<i>60/60 cum laude</i>
Date	26th June 2009
Title of qualification awarded	PhD degree
Principal subjects/occupational skills covered	Conduct of international, observational studies with multiple healthcare databases for the investigation of use and safety of psychotropic drugs in elderly people, with a dissertation of a thesis entitled: <i>"Use and safety of psychotropic drugs in elderly patients"</i>
Name and type of organisation providing education and training	Erasmus University Medical Center of Rotterdam, Netherlands
Level in national classification (if appropriate)	<i>Eligible</i>
Date	27th August 2008
Title of qualification awarded	Master of Science in Clinical Epidemiology
Principal subjects/occupational skills covered	<i>Pharmacoepidemiology, Decision making analysis, clinical trials, biostatistics, diagnostic and outcome research</i>
Name and type of organization providing education and training	Netherlands Institute for Health Sciences (NIHES), Netherlands
Level in national classification (if appropriate)	<i>Eligible</i>
Date	8th July 2006
Title of qualification awarded	Post-graduation degree in Clinical Pharmacology
Principal subjects/occupational skills covered	Clinical pharmacology, pharmacovigilance and pharmacoepidemiology with special involvement in the planning and conduct of observational studies through healthcare databases and a final dissertation entitled: "Role of healthcare database in the monitoring of safety of psychotropic drugs"
Name and type of organization providing education and training	University of di Messina
Level in national classification (if appropriate)	<i>50/50 cum laude</i>
Date	10th July 2003
Title of qualification awarded	Qualification to practicing physician
Principal subjects/occupational skills covered	Qualification to work as a medical doctor
Name and type of organization providing education and training	University of Messina, Messina - Italy
Level in national classification (if appropriate)	<i>Eligible</i>
Date	30th October 2002
Title of qualification awarded	Graduation in Medicine and Surgery
Principal subjects/occupational skills covered	<i>All basic and advanced disciplines related to medical school</i>

Name and type of organization
providing education and training

Level in national classification
(if appropriate)

University of Messina, Messina – Italy

110/110 *cum laude*

PERSONAL SKILLS AND COMPETENCES

AREA OF EXPERTISE

From 2009: Data integration and analysis from multiple healthcare databases for multicenter, international post-marketing studies concerning pharmacoepidemiology, drug utilization and Pharmacoeconomics.

From 2005: Medical Informatics

From 2002: Pharmacovigilance, Pharmacoepidemiology, Clinical Pharmacology

MOTHER TONGUE

Italian

OTHER LANGUAGES

English, Spanish, Dutch

Self-evaluation

English

Spanish

Dutch

Reading skills	Verbal skills	Writing skills
Excellent	Excellent	Excellent
Good	Good	Basic
Basic	Basic	Basic

SOCIAL SKILLS
AND COMPETENCES

Involvement in National and International research project

2025-

Coordinatore scientifico del progetto nazionale di Farmacovigilanza "Valutazione dell'Utilizzo e del profilo beneficio-rischio dei farmaci immunosoppressori tramite Linkage di dati Clinici ed Amministrativi Nelle malattie croniche infiammatorie immunomediate nel real-world setting Italiano – progetto VULCANO", finanziato dall'AIFA.

2023- Scientific coordinator of the project "Exploring the role of medicines in the induction as well as the management of sexual dysfunction through analysis of Big Data and "Smart data", funded by the Italian Ministry of the Education, Universities and Research (PRIN–PNRR 2023)

2023- Partner of the project "Bridging the gap: using foreign real-world data to inform interchangeable biosimilar approvals" funded by Food and Drug Administration – "Biosimilar User Fee Act (BsUFA) Research Grant (U01) Clinical Trials Optional"

2021-2024 Coordinator of Work Package 1 "Implementation of cohort-event monitoring in special populations (pregnant women, prior COVID- 19, immunocompromised, children, history of allergies)" of the project "Covid-Vaccine-Monitor: Safety monitoring of SARS-CoV-2 vaccines in EU Member States" funded by the European Medicine Agency

2020-2022 Partner of the Early COVID19 Vaccine Monitoring project funded by European Medicine Agency

2019 - 2024 Scientific coordinator of the "IN Search of early clinical and molecular Predictors of diagnosis and treatment response In patients with Rare Endocrine disorders: INSPIRE project" that has been funded by the Italian Ministry of the Education, Universities and Research (PRIN–Line C)

2019 – 2025 Scientific coordinator of the "Post-marketing eVALuation of benefit-risk profile of Originator biological drugs vs. biosimilars in dermatology, rheumatology, and gastroenterology through healthcare DB network and clinical REGistries –VALORE project", funded by the Italian Medicine Agency in the context of pharmacovigilance multiregional projects.

2019- Third party of IMI-funded project "ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now"

2018- 2021 Partner of the EMA Tender project “impact of risk minimization measure on use of retinoids among women of child-bearing potential”

2016-2019

Associate Partner of the European ADVANCE (Accelerated Development of VAccine beNefit-risk Collaboration in Europe) project, funded by the Innovative Medicine Initiative

2016-2020

Scientific coordinator of the multi-Regional pharmacovigilance project “Short- and long-term monitoring of the benefit-risk profile of intravitreal use of anti-VEGF drugs through clinical and claims database network”, funded by Italian Drug Agency

2016-2019

Scientific coordinator of the Regional pharmacovigilance project “Evaluation of prescribing appropriateness and safety of COPD drugs in general practice in Sicily”, funded by Italian Drug Agency

2013-2017

Responsible of Work Package of the project “Using Multidimensional Prognostic Indices (MPI) to improve the cost-effectiveness of interventions in frail older persons with multimorbidity” (MPI-AGE), funded by European Commission in the context of the Second Program of Community Action in the Field of Health

2012-2017

Responsible of Work Package of the project “Assessment of short- and long-term risk-benefit profile of biologics through healthcare database network in Italy”, funded by Italian Health Ministry.

2011-2012

Chief epidemiologist of the Observational Medical Outcomes Partnership/Food and Drug Administration funded project, “Detection of Long-Term Adverse Drug Reactions in Electronic Health Care Data”

2011-2016

Scientific coordinator of the project “Giovane Ricercatore 2009”, “Assessment of the safety of antipsychotic drugs in elderly with dementia: an international, population-based study using healthcare databases”, funded by Italian Health Ministry.

2011-2016

Partner of the international project “European Medical Information Framework (EMIF)”, funded in the context of 4th call IMI - Innovative Medicines Initiative.

2011-2012

Principal Investigator of the European Medicines Agency tender no. EMA/2011/39/CN “Risk of cardiac valve disorders associated with the use of bisphosphonates.”

2011-2016

Partner of the FP7 funded project “Safety Evaluation of Adverse Reactions in Diabetes - Safeguard” (www.safeguard-diabetes.org).

2010-2014

Responsible of Work Package “Analytic Database studies” in the FP7 funded project: “Arrhythmogenic potential of drugs: ARITMO project” (www.aritmo-project.org).

2008-2011

Scientific coordinator of the Work Package “System Validation” in the FP7 funded project “Early Detection of Adverse Drug Events by Integrative Mining of Clinical Records and Biomedical Knowledge: the EU-ADR project” (www.euadr-project.org).

TECHNICAL SKILLS AND COMPETENCES

Extraction, collection ex novo and analysis of healthcare data through electronic medical record databases and GP networks as well as claims and other RWD for drug utilization, pharmacovigilance, pharmacoepidemiology and pharmaco-economic studies; Drafting of protocols for observational studies.

INFORMATIC SKILLS AND COMPETENCES

In depth knowledge of potential and pitfalls of several claims and general practice database including IPCI; PHARMO, THIN, Health Search, Arianna database, as well EU and Italian claims databases and national and international spontaneous reporting databases (e.g. FDA-AERS, Eudravigilance, Vigibase). Development of electronic case report form for ex novo prospective data collection and applications for health.

OTHER SKILLS AND COMPETENCES

Teaching

2024-

Scientific coordinator of the Advanced course on Medication Review and Deprescribing at the University of Verona

2020-

Teaching Pharmacology at School of Medicine, Dentistry and Nursing – University of Verona

2020-2021

Teaching Pharmacology at Dental Hygiene and Physiotherapy courses – University of Verona

2016-

Scientific coordinator of the Master of Science program

“Pharmacovigilance, pharmacoepidemiology and Pharmacoeconomics: evaluations using real world data” at the University of Verona

2014-2017

Teaching the course of “Pharmacotherapeutics and drug utilization (2 CFU)” “Pharmacoeconomics”, “Monitoring of prescriptions and analyses of drug consumption in hospital” and “Prescribing Appropriateness” in the Post-Graduation School of Hospital Pharmacy of the University of Messina

From 2011 and up to 2020

Teaching Pharmacology at the Medicine and Surgery School, Dentistry School, Psychology School as well as Dietitian, Midwives, neurophysiology technicians' courses of the University of Messina

2010-2014

Teaching of the modules “Principles of identifying and recognizing adverse events and safety signals” of the international Master of Science

“European program in Pharmacovigilance and Pharmacoepidemiology: Eu2P” (www.eu2p.org) funded by Innovative Medicines Initiative - Call-2008.

2009

Teaching at the post-graduation courses of “Family Medicine” and “Geriatrics” at the Erasmus University Medical Center of Rotterdam (Olanda)

Other covered roles and positions

2025-

President of the Assembly of the Italian Directors of Clinical Pharmacology and Toxicology Postgraduation Schools

2023-

Member of Regional Technical Drug Committee of Veneto.

2023-

Member of Ethical Committee of North Area of Veneto as clinical pharmacologist

2023-

Vice-Dean of the Department of Diagnostics and Public Health (Department of excellence – 2023-2027)– University of Verona

2023-

Chair of the Big Data and RWE ISOP Special Interest Group

1st April – 30th October 2023

Member of the European Certified Pharmacologist (EuCP) committee of the Italian society of Pharmacology

2022-

Director of Post-graduation School in Clinical Pharmacology and Toxicology – University of Verona

2022-

Fellow of the International Society of Pharmacovigilance

2022-

International Society of Pharmacoepidemiology Nominating Committee

2020-

Scientific responsible of the academic spin-off INSPIRE – INnovative Solutions for medical Prediction and big data Integration in REal world setting

2020-

Fellow of the International Society for Pharmacoepidemiology

2019-

Advisory board member of Clinical Pharmacology section of Italian society of Pharmacology

2019-2022

Elected member of the Advisory Board of the International Society of Pharmacovigilance

2019-2020

Member of Start-up Committee of University of Messina

2019-

Chair of the Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics and Real-World Evidence (3F & RWE) Special Interest Group of the Italian Society of Pharmacology

2018-2019

Chair of Biologics & Biosimilars Special Interest Group of the International Society of Pharmacoepidemiology

2017-

Chair of Working group "Inventory of healthcare databases and multiple database studies" of the 'European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) at the European Medicine Agency

2016-

Member of the Steering Group of the European Network of Centers of Pharmacovigilance and Pharmacoepidemiology at the European Medicine Agency

2015-2019

Member of Sicilian Regional Drug Formulary and prescribing appropriateness committee

2015-2020

Data and Safety Monitoring Board member of the randomized clinical trial **FAIR PARK II** (*full project: "Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a European multicenter, parallel-group, placebo-controlled, randomized clinical trial of deferiprone"*)

2014-2019

Member of the Committee on the biosimilar use on behalf of the Sicilian Regional Health Department

2012

Member of the Local Chair Committee of the International Society Pharmacovigilance annual conference

2011 and 2019

Co-chair of the mid-year meeting of the International Society of Pharmacoepidemiology, Florence and Rome

2010-2013

Member of the technical group for the Geriatric Working Group of the Italian Drug Agency

Referee activities

2018-

Referee for HORIZON 2020, "Personalizing health care" and Societal Challenge 1 (Health section) areas.

2015-

Referee for European Research Advanced Grant 2014

2015-

Referee for Austrian Science Fund (FWF)

2007-2014

Referee for European Committee in the context of seven Framework Program, Health-Drug Safety area ('FP7-HEALTH-2007-Drug Safety')

Referee for the following international peer-reviewed scientific journals:

Pharmacoepidemiology and Drug Safety, BioDrugs, Expert Opinion on Drug Safety, Fundamental and Clinical Pharmacology, Psychiatric Services, Epilepsy Research, Neuroepidemiology; Schizophrenia Bulletin, BMC Medical Research Methodology, Drug Safety, Applied Clinical Informatics, Annals of Internal Medicine, New England Journal of Medicine, Annals of Rheumatic Disease, British Medical Journal and other peer-reviewed international journals in the area of clinical epidemiology, pharmacovigilance, pharmacoepidemiology and clinical pharmacology.

Member of the following Scientific Societies

Italian Society of Pharmacology (SIF)
International Society of Pharmacoepidemiology (ISPE)
International Society of Pharmacovigilance (ISOP)

Prizes

2010:

Grant from the *Fondazione Italiana per l'Educazione e lo Studio dei Farmaci, D.E.I. – Onlus*, for the best emerging scientific profiles concerning aspect of pharmacokinetic, pharmacodynamic, therapeutic appropriateness and pharmacovigilance

2009:

Best pharmacovigilance poster at the National Congress of the Italian Society of Pharmacology, Rimini, 14-17 October 2009

2007:

"Premio Giovane Ricercatore 2007" of the University of Messina

The article "Avillach P, Coloma P, Gini R, Schuemie M, Mouglin F, Dufour JC, Mazzaglia G, Giaquinto C, Fornari C, Herings R, Molokhia M, Pedersen L, Fourier-Réglat A, Fieschi M, Sturkenboom M, van der Lei J, Pariente A, and Trifirò G, on behalf of the EU-ADR consortium. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project*. *J Am Med Inform Assoc.* 2013 Jan 1;20(1):184-92" has been granted as "best article from the literature in the Health Information Systems in the 2014 in the International Medical Informatics Association Yearbook of Medical Informatics"

EDITORIAL COMMITTEE

Editor in Chief of Frontiers in Drug Safety and Regulation

Member of the Editorial Board of the following international peer-reviewed journals:

Drug Safety
Clinical Epidemiology
Clinical Drug Investigation
BioDrugs
Journal of Clinical Medicine
Pharmadvances

Publications

Full length publications on peer-reviewed international journals

1. Landi A, Reggiardo G, Didio A, D'Ercole A, Ceci A, Govere GS, Bonifazi D, Bonifazi F, Crisafulli S, Trifirò G, Kaguelidou F, Hakkarainen KM, Gvozdanović K, Barone-Adesi F, Ucciero A, Felisi M. Descriptive analysis of Pediatric Studies included in the European Union Post-Authorization Study Register from 2010 to 2023. Pediatric reports. In press.
2. Lopes S, Servadio M, Spini A, L'Abbate L, Ingrassiotta Y, Giometto S, Lucenteforte E, Leoni O, Zanforlini M, Ancona D, Stella P, Puccini A, Sapigni E, Rossi P, Ejlli L, Balducci F, Mangano MP, Ledda S, Carta P, Scarpelli RF, De Sarro G, Massari M, Spila Alegiani S, Addis A, Trifirò G, Belleudi V. Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project. Expert Opinion on Biological Therapy. In press.

3. Bellini A, Rosa AC, Spila Alegiani S, Massari M, Masiero L, Finocchietti M, Marino C, Agabiti N, Cardillo M, Luxi N, Trifirò G, Fiaschetti P, Davoli M, Addis A, Belleudi V. Survey on maintenance immunosuppressive therapy in patients undergoing solid organ transplantation: experiences from Italian transplant centers. *Recenti Prog Med.* 2024 Jul-Aug;115(7):341-349.
4. Luxi N, Bellitto C, Ciccimarra F, Cappello E, L'Abbate L, Bonaso M, Ajolfi C, Baldo P, Bonaiuti R, Costantino C, De Sarro G, Di Mauro C, Fava G, Ferri M, Firenze A, Furci F, Gallelli L, Leonardi L, Negri G, Pieraccini F, Poluzzi E, Sacripanti C, Sangiorgi E, Sapigni E, Senesi I, Tessari R, Trabace L, Vannacci A, Venturini F, Vitale F, Zodda D, Tuccori M, Trifirò G for the Italian network "ilmiovaccinoCOVID19". Cohort event monitoring of safety of COVID-19 vaccines: the Italian experience of the "ilmiovaccinoCOVID19 collaborating group". *Front. Drug Saf. Regul.*, In press.
5. Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T, Mulder E, L'Abbate L, Batel Marques F, Furci F, Farcas A, Giele-Eshuis J, Morton K, Sonderlichová S, Thurin NH, Villalobos F, Riefolo F, Sturkenboom MC, Trifirò G. Safety of COVID-19 vaccines among people with history of allergy: a European active surveillance study. *Vaccines.* In press
6. Morciano C, Massari M, Cutillo M, Belleudi V, Trifirò G, Mores N, Sapigni E, Puccini A, Zaroni G, Zorzi M, Monaco G, Leoni O, Del Zotto S, Samez S, Mayer F, Marano G, Menniti Ippolito F, Da Cas R, Traversa G, Spila Alegiani S. Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study. *Drug Safety.* In press.
7. Carollo M, Crisafulli S, Onder G, Trifirò G. Medication review e deprescribing nei vari setting assistenziali: un approccio per ottimizzare le terapie farmacologiche e migliorare gli esiti clinici dei pazienti. *Epidemiologia & Prevenzione.* In press
8. Crisafulli S, Ciccimarra F, Khan Z, Maccarrone F, Trifirò G. Pediatric therapeutic applications of Botulinum Toxin: Understanding clinical effectiveness and safety implications. In press. *Toxins.*
9. Bellitto C, Luxi N, Ciccimarra F, L'Abbate L, Raethke M, van Hunsel F, Lieber T, Mulder E, Riefolo F, Villalobos F, Thurin NH, Marques FB, Morton K, O'Shaughnessy F, Sonderlichová S, Farcas A, Janneke GE, Sturkenboom MC, Trifirò G. What is the safety of COVID-19 vaccines in immunocompromised patients? Results from the European "Covid Vaccine Monitor" active surveillance study. *Drug Saf.* In press.
10. Spini A, Pellegrini G, Ingrassiotta Y, L'Abbate L, Carollo M, Leoni O, Zanforlini M, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Ledda S, Carta P, Rossi P, Ejlli L, Sapigni E, Puccini A, Guarneri C, Gisondi P, Trifirò G. Switching pattern of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network. *Exp Op Biol Drugs.* In press.
11. Carollo M, Crisafulli S, Vitturi G, Besco M, Hinek D, Sartorio A, Tanara V, Spadacini G, Selleri M, Zanconato V, Minuz P, Zamboni M, Trifirò G. Clinical Impact of Medication Review and Deprescribing in Older Inpatients: A systematic review and meta-analysis. *Journal of American Geriatrics Society.* In press.
12. Spini A, L'Abbate L, Ingrassiotta Y, Pellegrini G, Carollo M, Ientile V, Leoni O, Zanforlini M, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Trifirò G. Development and validation of a META-algorithm to identify the indications of use of biological drugs approved for the treatment of immune-mediated inflammatory diseases from claims databases: insights from the VALORE Project. *Clinical Epidemiology.* In press.
13. Carollo M, Crisafulli S, Selleri M, Piccoli L, L'Abbate L, Trifirò G. Level of agreement among different drug-drug interaction checkers and summary of product characteristics of proton pump inhibitors. *JAMA Network Open.* In press.
14. de Filippis R, Kane JM, Arzenton E, Moretti U, Raschi E, Trifirò G, Barbui C, De Fazio P, Gastaldon C, Schoretsanitis G. Antipsychotic-related DRESS syndrome: analysis of individual case safety reports of the WHO pharmacovigilance database. *Drug safety.* In press.

15. Ingrasciotta Y, Vitturi G, Trifirò G. Pharmacological and benefit-risk profile of once-weekly basal insulin administration (icodec): addressing patients' unmet needs and exploring future applications. *Journal Clinical Medicine*. In press.
16. Marzona I, Stella P, Trifirò G, Corrao G. Dati regionali e loro ruolo nella pianificazione, programmazione e controllo a livello regionale. *Glob Reg Health Technol Assess*. 2024 Apr 25;11:101-104.
17. Crisafulli S, Ingrasciotta Y, Vitturi G, Fontana A, L'Abbate L, Alessi Y, Ferraù F, Cantarutti L, Lazzerini D, Cannavò S, Trifirò G. Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX Project. *Endocrine*. In press.
18. Raethke M, van Hunsel F, Luxi N, Lieber N, Bellitto C, Mulder E, Ciccimarra F, Riefolo F, Trifirò G, Sturkenboom MC. Frequency and timing of Adverse Reactions to COVID-19 Vaccines; a multi-country Cohort Event Monitoring Study. *Vaccine*. In press.
19. Crisafulli S, Ciccimarra F, Bellitto C, Carollo M, Carrara E, Stagi L, Triola R, Capuano A, Chiamulera C, Moretti U, Santoro E, Tozzi AE, Recchia G, Trifirò G. Artificial Intelligence for optimizing benefits and minimizing risks of pharmacological therapies: challenges and opportunities - *Frontiers in Drug Safety and Regulation*. In press.
20. Crisafulli S et al. Machine learning-based algorithms applied to drug prescriptions and other healthcare services in the Sicilian claims database for acromegaly identification as a model for rare disease earlier diagnosis. *Scientific reports*. In press.
21. Ciccimarra F, Luxi N, Bellitto C, L'Abbate L, Raethke M, Van Hunsel F, Lieber T, Mulder E, Riefolo F, Dureau-Pournin C, Farcas A, Batel Marques F, Morton K, Roy D, Sonderlichova S, Thurin NH, Villalobos F, Sturkenboom M, Trifirò G. Safety monitoring of COVID-19 vaccine in persons with prior SARS-COV-2 infection: a European multi-country study. *Vaccines*. In press.
22. Carollo M, Crisafulli S, Ciccimarra F, Andò G, Diemberger I, Trifirò G. Exploring the level of agreement among different drug-drug interaction checkers: A Comparative Study on Direct Oral Anticoagulants. *Expert Opinion On Drug Metabolism and Toxicology*. In press.
23. Cutroneo PM, Arzenton E, Furci F, Scapini F, Bulzomì M, Luxi N, Marco Caminati M, Senna G, Moretti U, Trifirò G. Safety of Biological Therapies for Severe Asthma: an analysis of suspected adverse reactions reported in the WHO pharmacovigilance database. *Biodrugs*. In press.
24. Tuccori M, Bate A, oretti U and Trifirò G. Traditional and Innovative Approaches for Signal Detection. *Front Drug Saf Regul*. DOI: 10.3389/fdsfr.2024.1373689.
25. Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifirò G, De Luca A. Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future. *CNS Drugs*. 2024 Jan;38(1):15-32.
26. Morciano C, Spila Alegiani S, Menniti Ippolito F, Belleudi V, Trifirò G, Zanoni G, Puccini A, Sapigni E, Mores N, Leoni O, Monaco G, Clagnan E, Zappetti C, Bovo E, Cuttillo M, Da Cas R, Massari M. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥ 12 years in Italy: A multi-database self-controlled case series study. *PLoS One* . 2024 Jan 19;19(1):e0290879.
27. Macca L, Li Pomi F, Ingrasciotta Y, Morrone P, Trifirò G, Guarneri C. Hidradenitis suppurativa and psoriasis: the odd couple. *Front Med (Lausanne)*. 2023 Jul 7;10:1208817.
28. Ingrasciotta Y, Spini A, L'Abbate L, Fiore ES, Carollo M, Ientile V, Isgrò V, Cavazzana A, Biasi V, Rossi P, Lucian E, Belleudi V, Poggi F, Scapigni E, Puccini A, Ancona D, Stella P, Pollina Addario W, Allotta A, Leoni O, Zanforlini M, Tuccori M, Gini R, Trifirò G. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: an external validity analysis of 66,639 biologic users from the Italian VALORE project. *Pharmacological Research*. In press.
29. Donker EM, Spitaleri Timpone P, Brinkman DJ, Richir MC, Papaioannidou P, Likic R, Sanz EJ, Christiaens T, Costa JN, De Ponti F, Gatti M, Böttiger Y, Kramers C, Pandit R, van Agtmael MA, Tichelaar J,

- Network of Teachers in Pharmacotherapy. The European List of Key Medicines for Medical Education: A Modified Delphi Study. *Clin Pharmacol Ther*. 2023 Dec 7. – **collaborating author**
30. Carollo M, Boccardi V, Crisafulli S, Conti V, Gnerre P, Medea G, Miozzo S, Omodeo Salè E, Pieraccini F, Zamboni M, Onder G, Trifirò G, on behalf of the Italian Scientific Consortium on medication review and deprescribing. Medication Review and Deprescribing in Different Healthcare Settings. A Position Statement from an Italian Scientific Consortium. *Aging Clinical and Experimental Research*. In press.
 31. Crisafulli S, Boccanegra B, Vitturi G, Trifirò G, De Luca A. Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence. *Brain Sciences*. 2023 Oct 10;13(10):1446. doi: 10.3390/brainsci13101446.
 32. Moleti M, Aversa T, Crisafulli S, Trifirò G, Corica D, Pepe G, Cannavò L, Di Mauro M, Paola G, Fontana A, Calapai F, Cannavò S, Wasniewska M. Global incidence and prevalence of differentiated thyroid cancer in childhood: systematic review and meta-analysis. *Front Endocrinol (Lausanne)*. 2023 Sep 19;14:1270518. doi: 10.3389/fendo.2023.1270518.
 33. Morciano C, Spila Alegiani S, Menniti Ippoliti F, Belleudi V, Trifirò G, Zanoni G, Puccini A, Sapigni E, Mores N, Leoni O, Monaco G, Clagnan E, Zappetti C, Bovo E, Da Cas R, Massari M. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥ 12 years in Italy: a multi-database self-controlled case series study. *MedRxiv*. 2023 Jan. doi: 10.1101/2023.01.17.23284585
 34. Trifirò G and Crisafulli S. Is antidepressant use a concern for COPD patients? *Thorax*. 2023 Dec 15;79(1):3-4. doi: 10.1136/thorax-2023-220517.
 35. Furci F, Luxi N, Senna G, Trifirò G. Anaphylaxis due to anti-allergic and anti-asthmatic biologics. *Current Opinion in Allergy & Clinical Immunology*. 2023 Oct 1;23(5):364-369. doi: 10.1097/ACI.0000000000000937.
 36. Crescioli G, Maggini V, Raschi E, Gonella LA, Luxi N, Ippoliti I, Di Giovanni V, Bonaiuti R, Firenzuoli N, Gallo E, Menniti-Ippolito F, Moretti U, Trifirò G, Vannacci A, Firenzuoli F, Lombardi N. Suspected adverse reactions to medications and food supplements containing *Serenoa repens*: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports. *Phytother Res*. 2023 Nov;37(11):5289-5299. doi: 10.1002/ptr.7960.
 37. Crisafulli S, Khan Z, Karatas Y, Tuccori M, Trifirò G. An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting. *Expert Opin Drug Saf*. 2023 Jan-Jun;22(5):373-380. doi: 10.1080/14740338.2023.2219892.
 38. Bahri P, Bowring G, Edwards BD, Anton C, Aronson JK, Caro-Rojas A, Hugman BPJ, Mol PG, Trifirò G, Ilic K, Daghfous R, Fermont I, Furlan G, Gaissmaier W, Geer MI, Hartigan-Go KY, Houýez F, Neth H, Norgela G, Oppamayun Y, Raynor DKT, Bouhlef M, Santoro F, Sultana J. Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance. *Drug Saf*. 2023 Jun;46(6):517-532. doi: 10.1007/s40264-023-01285-5.
 39. Ciccimarra F, Luxi N, Bellitto C, L' Abbate L, De Nardo P, Savoldi A, Yeomans A, Molokhia M, Tacconelli E, Trifirò G. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy. *BioDrugs*. 2023 Sep;37(5):675-684. doi: 10.1007/s40259-023-00601-w.
 40. Raethke M, van Hunsel F, Thurin NH, Dureau-Pournin C, Mentzer D, Kovačić B, Mirošević Skvrce N, De Clercq E, Sabbe M, Trifirò G, Luxi N, Giovanazzi A, Shakir S, Klungel OH, Schmikli S, Sturkenboom M. Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose. *Drug Saf*. 2023 Apr;46(4):391-404. doi: 10.1007/s40264-023-01281-9.
 41. Ahmadizar F, Luxi N, Raethke M, Schmikli S, Riefolo F, Saraswati PW, Bucsa C, Osman A, Liddiard M, Maques FB, Petrelli G, Sonderlichová S,

- Thurin NH, Villalobos F, Trifirò G, Sturkenboom M; ilmiovaccinoCOVID19 collaborating group. Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials. *Drug Saf.* 2023 Jun;46(6):575-585. doi: 10.1007/s40264-023-01304-5.
42. Scarpa M, Barbato A, Bisconti A, Burlina A, Concolino D, Deodato F, Di Rocco M, Dionisi-Vici C, Donati MA, Fecarotta S, Fiumara A, Galeone C, Giona F, Giuffrida G, Manna R, Mariani P, Pession A, Scopinaro A, Spada M, Spandonaro F, Trifirò G, Carubbi F, Cappellini MD. Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus. *Intern Emerg Med.* 2023 Apr;18(3):831-842. doi: 10.1007/s11739-023-03238-3.
 43. Ingrassiotta Y, Isgro V, Foti SS, Ientile V, Fontana A, L'Abbate L, Benoni R, Fiore ES, Tari M, Alibrandi A, Trifirò G. Testing of Coding Algorithms for Inflammatory Bowel Disease Identification, as Indication for Use of Biological Drugs, Using a Claims Database from Southern Italy. *Clin Epidemiol.* 2023 Mar 11;15:309-321. doi: 10.2147/CLEP.S383738.
 44. Crisafulli S, Cutroneo PM, Luxi N, Fontana A, Ferrajolo C, Marchione P, Sottosanti L, Zandoni G, Moretti U, Franzè S, Minghetti P, Trifirò G. Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System. *Drug Saf.* 2023 Apr;46(4):343-355. doi: 10.1007/s40264-023-01277-5.
 45. Reilev M, Jensen PB, Ranch LS, Egeberg A, Furu K, Gembert K, Hagg D, Haug U, Karlstad Ø, Reutfors J, Schäfer W, Schwartz S, Smits E, Holthius E, Herings R, Trifirò G, Kirchmayer U, Rosa AC, Belleudi V, Gini R, Støvring H, Hallas J. Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study. *BMJ Open.* 2023 Feb 1;13(2):e066057. doi: 10.1136/bmjopen-2022-066057.
 46. Crisafulli S, Poluzzi E, Lunghi C, Di Francesco V, Pellizzari L, Pasina L, Elli C, Trotta F, Cangini A, Trevisan C, Zazzara MB, Onder G, Trifirò G. Deprescribing as a strategy for improving safety of medicines in older people: clinical and regulatory perspective. *Front. Drug Saf. Regul.*, 23 December 2022. Doi: 10.3389/fdsfr.2022.1011701
 47. Reilev M, Jensen PB, Ranch LS, Egeberg A, Furu K, Gembert K, Hagg D, Haug U, Karlstad O, Reutfors J, Schafer W, Schwartz S, Smits E, Holthius E, Herings R, Trifiro G, Kirchmayer U, Rosa AC, Belleudi V, Gini R, Hallas J. Methodology of the BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases. *BMJ open.* In press.
 48. Crisafulli S, Poluzzi E, Lunghi C, Di Francesco V, Pellizzari L, Pasina L, Elli C, Trotta F, Cangini A, Trevisan C, Zazzara MB, Onder G, Trifirò G. Deprescribing as a strategy for improving safety of medicines in older people: clinical and regulatory perspective. *Front. Drug Saf. Regul.*, 23 December 2022.
 49. Ingrassiotta Y, Jin Y, Foti SS, Landon JE, Tari M, Mattace-Raso F, Kim SC, Trifirò G. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study. *Clin Rheumatol.* 2023 Apr;42(4):1047-1059. doi: 10.1007/s10067-022-06478-4
 50. Belleudi V, Rosa AC, Finocchietti M, Poggi FR, Marino ML, Massari M, Spila Alegiani S, Masiero L, Ricci A, Bedeschi G, Puoti F, Cardillo M, Pierobon S, Nordio M, Ferroni E, Zanforlini M, Piccolo G, Leone O, Ledda S, Carta P, Garau D, Lucenteforte E, Davoli M, Addis A; CESIT Study Group. An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project. *Front Pharmacol.* 2022 Sep 15;13:959267.
 51. Gastaldon C, Schoretsanitisb G, Arzenton E, Raschi E, Papola A, Ostuzzi G, Seifritz E., Fava G, Trifirò G, Barbui C. Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database. *Drug Saf.* 2022 Dec;45(12):1539-1549.
 52. Malikova MA, Trifirò G, Racagni G, Van Liew D, Webster P, Brahmabhatt TS. Establishing Patient Safety Monitoring in the Benefit-Risk Paradigm for Off-Label and Emergency Use of Medications for COVID-19: A

- Pharmacovigilance Perspective. *Front. Drug Saf. Regul.*, 26 October 2022.
53. Crisafulli S, Fontana A, L'Abbate L, Ientile V, Gianfrilli D, Cozzolino A, De Martino C, Ragonese M, Sultana J, Barone-Adesi F, Trifirò G. Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases. *Sci Rep.* 2022 Sep 23;12(1):15843.
 54. Gastaldon C, Salisbury A, Arzenton E, Raschi E, Papola D, Ostuzzia G, Moretti U, Trifirò G, Barbui C, Schoretsanitis G. Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database. *Psychol Med.* 2022 Sep 21:1-9.
 55. Crisafulli S, Trifirò G. The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs. *J. Recent Prog Med.* 2022 Jul-Aug;113(7):425-429.
 56. Massari M, Spila-Alegiani S, Morciano C, Spuri M, Marchione P, Felicetti P, Belleudi V, Poggi FR, Lazzarotti M, Ercolani M, Clagnani E, Bovo E, Trifirò G, Moretti U, Monaco G, Leoni O, Da Cas R, Petronzelli F, Tartaglia L, Mores N, Zanoni G, Rossi P, Samez S, Zappetti C, Marra AR, Menniti-Ippolito F on behalf of the TheShinISS-vax|COVID Surveillance Group. Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study. *PLoS Med.* 2022 Jul 28;19(7):e1004056.
 57. Maison P, Zureik M, Hivert V, Kjaer J, Hossein Khonsar R, Trifirò G, Ratignier-Carbonneil C. Real-World Evidence (RWE): A challenge for regulatory agencies - Discussion of the RWE Conference with the network of the European Medicine Agencies, patients, and experts. *Front Pharmacol.* 2022 Jul 26;13:969091.
 58. Fusaroli M, Isgrò V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, Raschi E, Poluzzi E, Trifirò G. Post-marketing surveillance of CAR-T cell therapies: analysis of the FDA Adverse Event Reporting System. *Drug Saf.* 2022 Aug;45(8):891-908.
 59. Crisafulli S, Recchia G, Santoro E, Trifirò G. Digital Therapeutics in perspective: from regulatory challenges to post-marketing surveillance. *Front. Drug Saf. Regul.*, 08 June 2022.
 60. Luxi N, Giovanazzi A, Arcolaci A, Bonadonna P, Crivellaro MA, Cutroneo PM, Ferrajolo C, Furci F, Guidolin L, Moretti U, Olivieri E, Petrelli G, Zanoni G, Senna G, Trifirò G. Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. *BioDrugs.* 2022 Jul;36(4):443-458.
 61. Porrini AM, Trifirò G, Mangrella M, Valle D, Berrino L, Simonato M. Quality of scientific data in pre and post-authorisation clinical drug trials. *Parmadvances.* Volume 4, special issue, 2022: 20-31.
 62. Guttadauria S, Bosch J, Tuzzolino F, Oliva E, Ekser B, Zito G, Cintorino D, di Francesco F, Li Petri S, Ricotta C, Calamia S, Magro B, Trifirò G, Alduino R, Barbàra M, Conaldi PG, Gallo A, Venuti F, Luca A, Bonsignore P, Pagano D. Donor simvastatin treatment is safe and might improve outcomes after liver transplantation: a randomized clinical trial. *Transplantation.* 2022 Dec 1;106(12):2379-2390.
 63. Roberto G, Girardi A, Barone-Adesi F, Pecere A, Ientile V, Bartolini C, Da Cas R, Spila-Alegiani S, Ferrajolo C, Francesconi P, Trifirò G, Poluzzi E, Baccetti F, Gini R. Time to treatment intensification in patients receiving DPP4 inhibitors versus sulfonylureas as the first add-on to metformin monotherapy: a retrospective cohort study. *Front Pharmacol.* 2022 May 30;13:871052.
 64. Di Lernia V, Macca L, Peterle L, Ingrassiotta Y, Trifirò G, Guarneri C. Efficacy of systemic drugs in pediatric psoriasis: evidence from five selected studies. *Front Pharmacol* 2022 Apr 5;13:847308.
 65. Trifirò G and Crisafulli S. Il ruolo della Real-World Evidence nello studio dell'epidemiologia delle malattie rare e nella valutazione post-marketing dei farmaci orfani. *Recenti Prog Med.* 2022 Jul-Aug;113(7):425-429.
 66. Trifirò G, Crisafulli S. A new Era of Pharmacovigilance: future challenges and opportunities. *Front. Drug Saf. Regul.*, 25 February 2022 <https://doi.org/10.3389/fdsfr.2022.866898>.

67. Onder G, Vetrano DL, Palmer K, Trevisan C, Amato L, Berti F, Campomori A, Catalano L, Corsonello A, Kruger P, Medea G, Nobili A, Trifirò G, Vecchi S, Veronese N, Marengoni A. Italian Guidelines on Management of Persons with Multimorbidity and Polypharmacy. *Aging Clin Exp Res*. 2022 May;34(5):989-996.
68. Sultana J, Crisafulli S, Almas M, Antonazzo IC, Baan E, Bartolini C, Bertuccio MP, Bonifazi F, Capuano A, Didio A, Ehrenstein V, Felisi M, Ferrajolo C, Fontana A, Francisca R, Fourrier-Reglat A, Fortuny J, Gini R, Hyeraci G, Hoeve C, Kontogiorgis C, Isgrò V, Lalagkas PN, L'Abbate L, Layton D, Landi A, Narduzzi S, Pereira L, Poulentzas G, Rafaniello C, Roberto G, Scondotto G, Sportiello L, Toma M, Toussi M, Verhamme K, Volpe E, Trifirò G. Overview of the EU PAS register post-authorization studies performed in Europe from September 2010 to December 2018. *Pharmacoepidemiol Drug Saf*. 2022 Jun;31(6):689-705.
69. Giuffrida G, Crisafulli S, Ferraù F, Fontana A, Alessi Y, Calapai F, Ragonese M, Luxi N, Cannavò S, Trifirò G. Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies. *J Endocrinol Invest*. 2022 Jun;45(6):1235-1246.
70. Villa F, Di Filippo A, Pierantozzi A, Genazzani A, Addis A, Trifirò G, Cangini A, Tafuri G, Settesoldi D, Trotta F. Orphan drugs prices and epidemiology of rare diseases: a crosssectional study in Italy in the years 2014-2019. *Frontiers in Medicine*. 2022 Feb 17;9:820757. doi: 10.3389/fmed.2022.820757
71. Crisafulli S, Ientile V, L'Abbate L, Fontana A, Linguiti C, Manna S, Mercaldo M, Pagliaro C, Vezzaro M, Santacà K, Lora R, Moretti U, Reno C, Fantini MP, Corrao S, Barbato D, Tari M and Trifirò G and the ITA-COVID: COV-OUT Group. COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. *J Clin Med*. 2021 Dec 23;11(1):51. doi: 10.3390/jcm11010051.
72. Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, Ravaldi C, Reno C, Tuccori M, Vannacci A, Zaroni G, Trifirò G** and IlmiovaccinoCOVID19 collaborating group. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. *Drug Safety*. 2021 Dec;44(12):1247-1269. doi: 10.1007/s40264-021-01131-6.
73. Crisafulli S, Luxi N, Coppini R, Capuano A, Scavone C, Zinzi A, Vecchi S, Onder G, Sultana J, Trifirò G. Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials. *BMC Fam Pract*. 2021 Oct 20;22(1):208. doi: 10.1186/s12875-021-01557-y.
74. Parravano M, Costanzo E, Scondotto G, Trifirò G, Virgili G. Anti-VEGF and other novel therapies for Neovascular Age Related Macular Degeneration: An Update. *Biodrugs*. 2021 Nov;35(6):673-692. doi: 10.1007/s40259-021-00499-2.
75. Trifirò G, Isgrò V, Ingrassiotta Y, Ientile V, L'Abbate L, Foti SS, Belleudi V, Poggi F, Fontana A, Moretti U, Lora R, Sabaini A, Senesi I, Sorrentino C, Puzo MR, Padula A, Fusco M, Giordana R, Solfrini V, Puccini A, Rossi P, Del Zotto S, Leoni O, Zanforlini M, Ancona D, Bavaro V, Garau D, Ledda S, Scondotto S, Allotta A, Tuccori M, Gini R, Bucaneve G, Franchini D, Cavazzana A, Biasi V, Spila Alegiani S, Massari M. Large-scale post-marketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the VALORE project. *BioDrugs*. 2021 Nov;35(6):749-764. doi: 10.1007/s40259-021-00498-3. Epub 2021 Oct 12.
76. Ingrassiotta Y, Isgrò V, Ientile V, Tari M, Trifirò G, Guarneri C. Are patients with psoriasis and psoriatic arthritis undertreated? A population-based study from Southern Italy. *J Clin Med*. 2021 Jul 31;10(15):3431. doi: 10.3390/jcm10153431.
77. Massari M, Spila Alegiani S, Fabiani M, Belleudi V, Trifirò G, Mancuso P, Menniti Ippolito F, Gini R, Leoni O, Luxi N, Giorgi Rossi P on behalf of ITA-COVID19 | FluVaccine. Association of influenza vaccination and prognosis in patients testing positive to SARS-COV-2 swab test: a large-scale Italian multi-database cohort study. *Vaccines (Basel)*. 2021 Jul 1;9(7):716. doi: 10.3390/vaccines9070716.

78. Crisafulli S, Cutroneo PM, Verhamme K, Ferrajolo C, Ficarra V, Sottosanti L, Di Giovanni V, Spina E, Trifirò G. Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. *European Urology Focus. Eur Urol Focus.* 2021 Jul 15:S2405-4569(21)00180-2. doi: 10.1016/j.euf.2021.07.001.
79. Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, Ferraù F, Gianfrilli D, Cozzolino A, De Martino MC, Gatto F, Barone-Adesi F, Cannavò S, Trifirò G. Global epidemiology of acromegaly: a systematic review and meta-analysis. *Eur Journal Endocrinology.* 2021 Jul 1;185(2):251-263. doi: 10.1530/EJE-21-0216.
80. Grova M, Ingrassiotta Y, Crispino F, Isgrò I, Calapai F, Macaluso FS, Mattace-Raso F, Trifirò G, Orlando A. Safety and potential interaction of drugs for the treatment of inflammatory bowel disease in elderly patients. *Minerva Gastroenterol (Torino).* 2021 May 31. doi: 10.23736/S2724-5985.21.02919-3.
81. Crisafulli S, Bertino L, Fontana A, Calapai F, Ingrassiotta Y, Berretta M, Trifirò G, Guarneri C. Incidence of skin cancer in patients with chronic inflammatory cutaneous diseases on targeted therapies: a systematic review and meta-analysis of observational studies. *Front Oncol.* 2021 Jun 3;11:687432. doi: 10.3389/fonc.2021.687432.
82. Gembillo G, Ingrassiotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, Trifirò G. Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia. *International journal of molecular sciences.* 2021 May 1;22(9):4824. doi: 10.3390/ijms22094824.
83. Spila Alegiani S, Crisafulli S, Giorgi Rossi P, Mancuso P, Salvarani C, Atzeni F, Gini R, Kirchmayer U, Belleudi V, Kurotschka PK, Leoni O, Ludergrani M, Ferroni E, Baracco S, Massari M, Trifirò G and the ITA-COVID-19 Network. Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. *Rheumatology (Oxford).* 2021 Oct 9;60(SI):SI25-SI36. doi: 10.1093/rheumatology/keab348.
84. Di Martino M, Alagna M, Lallo A, Gilmore KJ, Francesconi P, Profili F, Scondotto S, Fantaci G, Trifirò G, Isgrò V, Davoli M, Fusco D. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication. *BMC Cardiovasc Disord.* 2021 Apr 14;21(1):180. doi: 10.1186/s12872-021-01969-9.
85. Ingrassiotta Y, Fontana A, Mancuso A, Ientile V, Sultana J, Uomo I, Pastorello M, Calabrò P, Andò G, Trifirò G. Comparison of direct oral anticoagulant use for the treatment of non-valvular atrial fibrillation in pivotal clinical trials vs. the real-world setting: a population-based study from Southern Italy. *Pharmaceuticals (Basel).* 2021 Mar 25;14(4):290. doi: 10.3390/ph14040290.
86. Perrone-Filardi P, Minghetti P, Menditto E, Bianchi S, Scaglione F, Trifirò G, Piccinocchi G, Corona T, Gambarelli G, Izzi C, Misciagna V, Putignano D, Lopatriello S, Cafiero D. The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus. *J Cardiovasc Med (Hagerstown).* 2021 Apr 1;22(4):246-258.
87. Oppelt KA, Kuiper JG, Ingrassiotta Y, Ientile V, Herings RMC, Tari M, Trifirò G, Haug U. Characteristics and absolute survival of metastatic colorectal cancer patients treated with biologics: a real-world data analysis from three European countries. *Front Oncol.* 2021 Mar 5;11:630456. doi: 10.3389/fonc.2021.630456.
88. Cutroneo P, Ingrassiotta Y, Isgrò V, Venanzi Rullo E, Berretta M, Fiorica F, Trifirò G, Guarneri C. Psoriasis and psoriasiform reactions secondary to Immune Checkpoint Inhibitors. *Dermatol Ther.* 2021 Mar;34(2):e14830. doi: 10.1111/dth.14830.
89. Ingrassiotta Y, Sultana J, Formica D, Ientile V, Aiello A, Chinellato A, Tari DU, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Rossi M, Santoro D, Trifirò G on behalf of the Italian Biosimilars Network (I-BioNetwork). Direct healthcare costs of chronic kidney disease management in Italy: what cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents? *Pharmacoeconomol Drug Saf.* 2021 Jan;30(1):65-77.

90. Scondotto G, Sultana J, Vadalà M, Avitabile T, Cillino S, Foti SS, Labbate L, Longo A, Mirabelli E, Puzo MR, Rapisarda C, Ibanez Toro P, Trombetta CJ, Trifirò G, Virgili G; for ITACA (Intravitreal Therapy Administrative and Clinical Accrue) Network. Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southern Italy. *Eur J Ophthalmol*. 2022 Sep;32(5):3064-3073. doi: 10.1177/11206721211073402.
91. Thurin NH, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, Paoletti O, Nordeng H, Wallach-Kildemoes H, Ehrenstein V, Dudukina E, MacDonald T, De Paoli G, Loane M, Damase-Michel C, Beau AB, Droz-Perroteau C, Lassalle R, Bergman J, Swart K, Schink T, Caverio-Carbonell C, Barrachina-Bonet L, Gomez-Lumbreras A, Giner-Soriano M, Aragón M, Neville AJ, Puccini A, Pierini A, Ientile V, Trifirò G, Rissmann A, Leinonen MK, Martikainen V, Jordan S, Thayer D, Scanlon I, Georgiou ME, Cunningham M, Swertz M, Sturkenboom M, Gini R. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. *Clin Pharmacol Ther*. 2022 Jan;111(1):321-331. doi: 10.1002/cpt.2476.
92. Scondotto G, Crisafulli S, Antonazzo IC, Virgili G, Trifirò G, Sultana J. Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research. *Expert Opin Drug Saf*. 2022 Feb;21(2):205-214. doi: 10.1080/14740338.2021.1957829.
93. Ingrasciotta Y, Bertuccio MP, Crisafulli S, Ientile V, Muscianisi M, L'Abbate L, Pastorello M, Provenzano V, Scorsone A, Scondotto S, Trifirò G. Real world use of antidiabetic drugs in the years 2011-2017: a population-based study from Southern Italy. *Int J Environ Res Public Health*. 2020 Dec 18;17(24):E9514. doi: 10.3390/ijerph17249514.
94. Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifirò G. Challenges for drug repurposing in the COVID-19 pandemic era. *Front Pharmacol*. 2020 Nov 6;11:588654. doi: 10.3389/fphar.2020.588654
95. Gozzo L, Benfatto G, Giorgianni F, Sultana J, Rossi E, Longo L, Mansueto S, Vitale DC, Savoca C, Caraci F, De Rosa M, Trifirò G, Drago F. Beyond the budget silo approach: estimating health system sustainability for future dementia drugs. *Pharmadvances*. Vol. 2 (No. 3) 2020 October, 68-78 doi: 10.36118/pharmadvances.03.2020.01
96. Ferroni E, Giorgi Rossi P, Spila Alegiani S, Trifirò G, Pitter G, Leoni O, Cereda D, Marino M, Pellizzari M, Fabiani M, Riccardo F, Sultana J, Massari M, the ITA-COVID19 working Group. Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network. *Clin Epidemiol*. 2020 Dec 8;12:1337-1346.
97. Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C, De Waure C, Ferlazzo G, Trifirò G. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks and public health considerations. *Expert Rev Vaccines*. 2020 Oct;19(10):919-936.
98. Trifirò G, Massari M, Da Cas R, Menniti Ippolito F, Sultana J, Crisafulli S, Giorgi Rossi P, Marino M, Zorzi M, Bovo E, Leoni O, Ludergrani M, Spila Alegiani S; ITA-COVID-19: RAAS inhibitor group. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. *Drug Saf*. 2020 Dec;43(12):1297-1308.
99. Viola A, Fontana A, Belvedere A, Scoglio R, Costantino G, Sitibondo A, Muscianisi M, Inferrera S, Bruno LM, Alibrandi A, Trifirò G & Fries W. Point-of-Care-test screening versus Case Finding for pediatric celiac disease: a pragmatic study in primary care. *Scand J Gastroenterol*. 2020 Oct;55(10):1176-1184.
100. Sultana J, Trifirò G, Ientile V, Fontana A, Rossi F, Capuano A, Ferrajolo C. Traceability of paediatric antibiotic purchasing pathways in Italy: a nationwide real-world drug utilisation analysis. *Front Pharmacol*. 2020 Aug 12;11:1232.
101. Di Martino M, Alagna M, Francesconi P, Profili F, Scondotto S, Fantaci G, Trifirò G, Isgrò V, Davoli M, Fusco D. Adherence to chronic polytherapy in the secondary prevention of myocardial infarction: a matter of gender? *Ital J Gender-Specific Med* 2020;6(3):148-151.

102. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 patients: overview of antibacterial, antiviral, immunomodulating and torsadogenic effects. *Drug Saf.* 2020 Aug;43(8):691-698.
103. Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, di Paola ED, Citraro R, Luzzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. *Curr Med Res Opin.* 2020 Sep;36(9):1457-1463.
104. Sultana J, Giorgianni F, Scondotto G, Ientile V, Cananzi P, Leoni O, Pollina Addario W, De Sarro G, De Francesco A, Puzo MR, Renoux C, Trifirò G. Association between aflibercept and serious non-ocular haemorrhage compared to ranibizumab: a multi-centre observational cohort study. *Drug Saf.* 2020 Sep;43(9):943-952.
105. Crisafulli S, Isgro V, La Corte L, Atzeni F, Trifirò G. Potential role of anti-Interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks. *BioDrugs.* 2020 Aug;34(4):415-422.
106. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global Epidemiology of Duchenne Muscular Dystrophy: An Updated Systematic Review and Meta-Analysis. Crisafulli S; Sultana J; Fontana A; Salvo F; Messina S; Trifirò G. *Orphanet J Rare Dis.* 2020 Jun 5;15(1):141.
107. Caramori G, Cipolla G, Relo R, Pasciuta E, Catalano D, Lo Bello F, Coppolino I, Andò F, Ruggeri P, Proietto A, Buccafusca M, Cutroneo PM, Trifirò G. Diffuse alveolar hemorrhage after first administration of alemtuzumab in a patient with multiple sclerosis. *Monaldi Arch Chest Dis.* 2020 Jul 24;90(3).
108. Isgro V, Sultana J, Fontana A, Ientile V, Alecci U, Scoglio R, Magliozzo F, Scondotto S, Caramori G, Cazzola M, Trifirò G. Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions. *ERJ Open Res.* 2020 Aug 17;6(3):00279-2020.
109. Cutroneo P, Isgro V, Ientile V, Santarpia MC, Ferlazzo G, Fontana A, Carrega P, Matarangolo E, Spina E, Trifirò G. Safety profile of Immune Checkpoint Inhibitors: an analysis of Italian Spontaneous Reporting System. *Br J Clin Pharmacol.* 2020 Jun 4. doi: 10.1111/bcp.14413.
110. Capuano A, Scaglione F, Berrino L, Del Re M, Bernardini R, Chiamulera C, D'Avolio A, Trifirò G, Clementi E, Danesi R, Pani L, Racagni G. Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary. Vol. 2 (No.1) 2020 April, 6-10 -doi: 10.36118/pharmadvances.01.2020.03
111. Trifirò G, Berrino L, Del Re M, Bernardini R, Chiamulera C, D'Avolio A, Scaglione F, Capuano A, Clementi E, Danesi R, Pani L, Catapano A, Racagni G on behalf of the Section of Clinical Pharmacology of Italian Society of Pharmacology. Official statement of the Italian Society of Pharmacology on the use of ACE-inhibitors or angiotensin receptor blockers in COVID-19 infection *Pharmadvances.* Vol. 2 (No.1) 2020 April, 1-5. doi: 10.36118/pharmadvances.01.2020.01.
112. Trifirò G, Crisafulli S, Andò G, Racagni G, Drago F on behalf of the Italian Society of Pharmacology. Should the patients on treatment with ACE-inhibitors or angiotensin receptor blockers be switched to other anti-hypertensive drugs to prevent or improve prognosis of novel coronavirus disease 2019 (COVID-19)? *Drug Saf.* 2020 Jun;43(6):507-509.
113. Cruz-Jentoft AJ, Daragjati J, Fratiglioni L, Maggi S, Mangoni AA, Mattace-Raso F, Paccalin M, Polidori MC, Topinkova E, Ferrucci L, Pilotto A; MPI_AGE Investigators. Using the Multidimensional Prognostic Index (MPI) to improve cost-effectiveness of interventions in multimorbid frail older persons: results and final recommendations from the MPI_AGE European Project. *Aging Clin Exp Res.* 2020 May;32(5):861-868.
114. Gini R, Sturkenboom MCJM, Sultana J, Cave A, Landi A, Pacurariu A, Roberto G, Schink T, Candore G, Slattery J, Trifirò G, on behalf of the Working Group 3 of ENCePP. Different strategies to execute multi-

- database studies for medicines surveillance in real world setting: a reflection on the European model. *Clin Pharmacol Ther.* 2020 Aug;108(2):228-235.
115. Kaguelidou F, Holstiege J, Schink T, Bezemer I, Poluzzi E, Mazzaglia G, Pedersen L, Sturkenboom M, **Trifirò G.** Use of antipsychotics in children and adolescents: A picture from the ARITMO population-based European cohort study. *Epidemiol Psychiatr Sci.* 2020 Apr 20;29:e117.
 116. Sultana J, **Trifirò G.** The potential role of big data in the detection of adverse drug reactions. *Expert Rev Clin Pharmacol.* 2020 Mar;13(3):201-204.
 117. Sultana J, Scondotto G, Cutroneo PM, Morgante F, **Trifirò G.** Intravitreal anti-VEGF drugs and signals of dementia and Parkinson- like events: analysis of the VigiBase database of spontaneous reports
Running title: Use of anti-VEGF and neurodegeneration. *Front Pharmacol.* 2020 Mar 12;11:315. doi: 10.3389/fphar.2020.00315.
 118. Trifirò G. Fonti dati disponibili in Italia per gli studi post-marketing sui farmaci. *Recenti Prog Med.* 2019 Nov;110(11):528.
 119. Sultana J, Azzopardi-Muscat N, Coleiro B, Grech L, Muscat M, Santoro D & Trifirò G. Pharmacological therapy in a rare disease: challenges in the long-term management of granulomatosis with polyangiitis. *Expert Opinion on Orphan Drugs*, 7:12, 521-523.
 120. Cortesi PA, Castaman G, Trifirò G, Seroo Creazzola S, Improta G, Mazzaglia G, Molinari AC, Mantovani LG. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. *Thromb Haemost.* 2020 Feb;120(2):216-228.
 121. Pottegård A, Klungel O, Winterstein A, Huybrechts K, Hallas J, Schneeweiss S, Evans S, Bate A, Pont L, Trifirò G, Smith M, Bourke A. The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. *Pharmacoepidemiol Drug Saf.* 2019 Dec;28(12):1640-1641.
 122. Ingrassiotta Y, Belleudi V, Trotta F, Addis A, Fontana A, Chinellato A, Ientile V, Tari DU, Roberto G, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Rossi M, Trifirò G on behalf of the Italian Biosimilars Network (I-BioNetwork). In search of predictors of switching between erythropoiesis-stimulating agents in clinical practice: a multi-Regional cohort study. *BioDrugs.* 2020 Feb;34(1):55-64.
 123. Sultana J, Ingrassiotta Y, Giorgianni F, Menditto E, Scuteri A, Tari M, Tari D, Basile G, Trifirò G. Analgesic drug use in elderly persons: a population-based study in Southern Italy. *PLoS One.* 2019 Sep 19;14(9):e0222836. doi: 10.1371/journal.pone.0222836.
 124. Ingrassiotta Y, Lacava V, Marcianò I, Giorgianni F, Tripepi G, D'Arrigo G, Chinellato A, Tari DU, Santoro D, Trifirò G. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. *BMC Nephrol.* 2019 Sep 14;20(1):359.
 125. Sultana J, Trotta F, Addis A, Brown JS, Gil M, Menniti-Ippolito F, Milozzi F, Suissa S, Trifirò G. Healthcare database networks for drug regulatory policies: international workshop on the experience of Canadian, US and Spanish systems and future steps for Italy". *Drug Saf.* 2020 Jan;43(1):1-5.
 126. Sultana J, Fontana A, Giorgianni F, Tillati S, Cricelli C, Pasqua A, Paterno E, Ballard C, Sturkenboom M, Trifirò G. Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. *Drug Saf.* 2019 Dec;42(12):1471-1485.
 127. Ingrassiotta Y, Sultana J, Kirchmayer U, Trifirò G. Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy. *BioDrugs.* 2019 Aug;33(4):345-352.
 128. Belleudi V, Trotta F, Addis A, Ingrassiotta Y, Ientile V, Tari M, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Trifirò G; Italian Biosimilar Network (ItaBioNet). Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic

- Kidney Disease in a Large-Scale Italian Cohort Study. *Drug Saf.* 2019 Dec;42(12):1437-1447.
129. Fries W, Belvedere A, Cappello M, Orlando A, Trifirò G. Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response? *Clin Drug Investig.* 2019 Aug;39(8):799-803.
 130. Schneeweiss S, Brown JS, Bate A, Trifirò G, Bartels DB. Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. *Clin Pharmacol Ther.* 2020 Apr;107(4):827-833.
 131. Crisafulli S, Sultana J, Ingrassiotta Y, Addis A, Cananzi P, Cavagna L, Conter V, D'Angelo G, Ferrajolo C, Mantovani L, Pastorello M, Scondotto S, Trifirò G. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. *Expert Opin Drug Saf.* 2019 Jun;18(6):497-509.
 132. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. *J Clin Oncol.* 2019 May 20;37(15):1336-1351.
 133. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. *Blood Adv.* 2019 3:1197-1210.
 134. Agostoni E, Barbanti P, Frediani F, Trifirò G, Burgio L, di Nola L, Pegoraro V, Pulimeno S, Cepparulo M. Real-world insights on the management of migraine patients: an Italian nationwide study. *Curr Med Res Opin.* 2019 Sep;35(9):1545-1554.
 135. Sultana J, Hurtado I, Bejarano-Quisoboni D, Giorgianni F, Huybrechts KF, Lu Z, Patorno E, Sanfèlix-Gimeno G, Tari DU, Trifirò G. Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. *Eur J Clin Pharmacol.* 2019 Jul;75(7):1005-1015.
 136. Roberto G, Barone-Adesi F, Giorgianni F, Pizzimenti V, Ferrajolo C, Tari M, Bartolini C, Da Cas R, Maggini M, Spila-Alegiani S, Francesconi P, Trifirò G, Poluzzi E, Baccetti F, Gini R. Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas. *BMC Endocr Disord.* 2019 Feb 7;19(1):18.
 137. Ferrajolo C et al. Gender Differences in Outpatient Pediatric Drug Utilization: a Cohort Study from Southern Italy. *Front Pharmacol.* 2019 Feb 5;10:11.
 138. Sultana J, Giorgianni F, Rea F, Lucenteforte E, Lombardi N, Mugelli A, Vannacci A, Liperoti R, Kirchmayer U, Vitale C, Chinellato A, Roberto G, Corrao G, Trifirò G. All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy. *Expert Opin Drug Metab Toxicol.* 2019 Feb;15(2):179-188.
 139. Sultana J, Leal I, de Wilde M, de Ridder M, van der Lei J, Sturkenboom M, Trifirò G. Identifying Data Elements to Measure Frailty in a Dutch Nationwide Electronic Medical Record Database for Use in Postmarketing Safety Evaluation: An Exploratory Study. *Drug Saf.* 2019 Jun;42(6):713-719.
 140. Pizzimenti V, Formica D, Sultana J, Lucchesi S, Aiello A, Ientile V, Trifirò G. Access of Medicines to the Market: Three Years' Experience of the Sicilian Regional Drug Formulary. *Gazzetta Medica Italiana - Archivio per le Scienze Mediche* 2020 May;179(5):317-25.
 141. Sultana J, Moretti U, Trifirò G et al. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. *Drug Saf.* 2019 May;42(5):683-687.
 142. Ingrassiotta Y, Crisafulli S, Pizzimenti V, Marcianò I, Mancuso A, Andò G, Corrao G, Capranzano P, Trifirò G. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. *Expert Opin Drug Metab Toxicol.* 2018 Oct;14(10):1057-1069.
 143. Rea F, Calusi G, Franchi M, Vetrano DL, Roberto G, Bonassi S, Kirchmayer U, Chinellato A, Bettiol A, Sultana J, Mugelli A, Corrao G; I-

- GRADE Investigators. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation. *Drugs Aging*. 2018 Dec;35(12):1099-1108.
144. Trifirò G. et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? *Drug Saf*. 2019 Mar;42(3):347-363.
 145. Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, Ingrassiotta Y, Salvo F, Spina E, Trifirò G. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. *Expert Opin Drug Saf*. 2018 Jul;17(7):681-695.
 146. Trifirò G, Marcianò I, Cutroneo PM, Spina E, Mirabelli E, Trombetta CJ, Morgante F. Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. *Front Pharmacol*. 2018 Jun 8;9:608.
 147. Patadia VK, Schuemie MJ, Coloma PM, Herings R, van der Lei J, Sturkenboom M, Trifirò G. Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction. *Front Pharmacol*. 2018 Jun 6;9:594.
 148. Marcianò I, Randazzo MP, Panagia P, Intelisano R, Sgroi C, Ientile V, Cannavò S, Guarneri C, Reitano P, Spina E, Trifirò G. Real world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study from Southern Italy in the years 2010-2014. *G Ital Dermatol Venereol*. 2020 Aug;155(4):441-451.
 149. Marcianò I, Ingrassiotta Y, Giorgianni F, Ientile V, Chinellato A, Tari DU, Gini R, Cannavò S, Pastorello M, Scondotto S, Cananzi P, Traversa G, Trotta F, Belleudi V, Addis A, Trifirò G. Pattern of use of biosimilar and originator somatropin in Italy: a population-based multiple databases study during the years 2009-2014. *Front Endocrinol (Lausanne)*. 2018 Mar 13;9:95.
 150. Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, Cazzola M, Cricelli C, Caputi AP, Trifirò G. Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. *NPJ Prim Care Respir Med*. 2018 Mar 23;28(1):10.
 151. Gatto F, Trifirò G, Lapi F, Cocchiara F, Campana C, Dell'Aquila C, Ferrajolo C, Arvigo M, Cricelli C, Giusti M, Ferone D. Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. *Endocrine*. 2018 Sep;61(3):533-541.
 152. Ingrassiotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. *Drug Saf* 2018 Nov;41(11):1013-1022.
 153. Comoretto RI, Rea F, Lucenteforte E, Mugelli A, Trifirò G, Cascini S, Roberto G, Chinellato A, Filippelli A, Corrao G; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. *Eur J Clin Pharmacol*. 2018 Aug;74(8):1061-1070.
 154. Roberto G, Bartolini C, Rea F, Onder G, Vitale C, Trifirò G, Kirchmayer U, Chinellato A, Lucenteforte E, Corrao G, Mugelli A, Lapi F, Gini R; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. *Eur J Clin Pharmacol*. 2018 May; 74(5):637-643.
 155. Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Sauermann R, Klaus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Sebesta R, Laius O, Karr A, Beck M, Martikainen J, Selke G, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogeale A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnusson E, and Simoons S. Policies for biosimilar uptake in Europe: a comparative analysis. *PLoS One*. 2017 Dec 28;12(12):e0190147.

156. Trifirò G, Marcianò I, Ingrasciotta Y. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. *Expert Opinion On Biological Therapy*. Expert Opin Biol Ther. 2018 Mar;18(3):309-315.
157. Pilotto A, Polidori MC, Veronese N, Panza F, Arboretti Giancristofaro R, Pilotto R, Daragjati J, Carrozzo E, Prete C, Gallina P, Padovani A, Maggi S, on behalf of the Multidimensional Prognostic Index (MPI)_Age Project Investigators. Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment. *J Am Med Dir Assoc*. 2018 Feb;19(2):162-168.
158. Scoglio R, Trifirò G, Sandullo A, Marangio G, D'Agate C, Costa S, Pellegrino S, Alibrandi A, Aiello A, Currò G, Cuzzupè C, Comisi F, Amato S, Conti Nibali R, Oteri S, Magazzu G, Carroccio A; Sicilian Celiac Disease Study Group. Diagnostic Yield of 2 Strategies for Adult Celiac Disease Identification in Primary Care. *J Clin Gastroenterol*. 2019 Jan;53(1):15-22.
159. Sultana J, Calabro M, Garcia-Serna R, Ferrajolo C, Crisafulli C, Mestres J, Trifirò G. Biological substantiation of antipsychotic-associated pneumonia: systematic literature review and computational analyses. *PLoS One*. 2017 Oct 27;12(10):e0187034.
160. Sultana J, Fontana A, Giorgianni F, Basile G, Patorno E, Pilotto A, Molokhia M, Stewart R, Sturkenboom M, Trifirò G. Can information on functional and cognitive status improve short-term mortality risk prediction among community-dwelling older people? A cohort study using a UK primary care database. *Clin Epidemiol*. 2017 Dec 19;10:31-39.
161. Biffi A, Scotti L, Rea F, Lucenteforte E, Chinellato A, Vetrano DL, Vitale C, Agabiti N, Sultana J, Roberto G, Mugelli A, Corrao G; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Adherence to Antidepressants and Mortality in Elderly Patients with Cardiovascular Disease. *Clin Drug Investig*. 2018 Jul;38(7):593-602.
162. Biffi A, Rea F, Scotti L, Mugelli A, Lucenteforte E, Bettiol A, Chinellato A, Onder G, Vitale C, Agabiti N, Trifirò G, Roberto G, Corrao G, on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Antidepressants and the risk of arrhythmia in elderly affected by a previous cardiovascular disease: a real-life investigation from Italy. *Eur J Clin Pharmacol*. 2018 Jan;74(1):119-129.
163. Lucchesi S*, Marcianò I*, Panagia P, Intelisano R, Randazzo MP, Sgroi C, Altavilla G, Santarpia M, Adamo V, Franchina T, Ferraù F, Reitano P, Trifirò G. Assessment of the pattern of use and costs of biological drugs in oncology: a 5-year picture from Southern Italy. *Clin Drug Investig*. 2018 Mar;38(3):269-278.
164. Lepelaars LRA, Renda F, Pani L, Pimpinella G, Leufkens HGM, Trifirò G, Tafuri G, Mantel-Teeuwisse AK, Trotta F. Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European Risk Management Plans. *Br J Clin Pharmacol*. 2018 Apr;84(4):738-763.
165. Bettiol A, Lucenteforte E, Vannacci A, Lombardi N, Onder G, Agabiti N, Vitale C, Trifirò G, Corrao G, Roberto G, Mugelli A, Chinellato A, for the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Calcium channel blockers in secondary cardiovascular prevention and risk of acute events: real-world evidence from nested case-control studies on Italian hypertensive elderly. *Clin Drug Investig*. 2017 Dec;37(12):1165-1174.
166. Trifirò G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. *Drug Saf*. 2018 Feb;41(2):143-149.
167. Poluzzi E, Diemberger I, De Ridder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, Pilgaard Ulrichsen S, Boriani G, Sturkenboom MCJ, De Ponti F, Trifirò G. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in 5 European countries from the ARITMO project. *Eur J Clin Pharmacol*. 2017 Nov;73(11):1499-1510.
168. Diemberger I, Raschi E, Trifirò G. Balancing the need for personalization of QT correction and generalization of study results: going beyond TQT studies. *Clin Drug Investig*. 2017 Oct;37(10):985-988.

169. Oteri G, Trifirò G, Peditto M, Lo Presti L, Marcianò I, Giorgianni F, Sultana J, Marcianò A. Treatment of medication-related osteonecrosis of the jaws and its impact on patient's quality of life: a single center 10 years' experience from Southern Italy. *Drug Saf.* 2018 Jan;41(1):111-123.
170. La Gamba F, Corrao G, Romio S, Sturkenboom M, Trifirò G, Schink T, de Ridder M. Combining evidence from multiple electronic healthcare databases: performances of One- and Two-stage Meta-analysis in matched case-control studies. *Pharmacoepidemiol Drug Saf.* 2017 Oct;26(10):1213-1219.
171. Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, Foskett N, Gini R, Forrest Gordon M, Gungabissoon U, Mayer MA, Novak G, Rijnbeek P, Trifirò G, van der Lei J, Visser PJ, Stewart R. Dementia prevalence and incidence in a federation of European Electronic Health Record (EHR) databases – the European Medical Informatics Framework (EMIF) resource. *Alzheimers Dement.* 2018 Feb;14(2):130-139.
172. Cutroneo PM, Giardina C, Ientile V, Potenza S, Sottosanti L, Ferrajolo C, Trombetta CJ, Trifirò G. Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. *Drug Saf.* 2017 Nov;40(11):1131-1140.
173. Bureau ML, Liuu E, Christiaens L, Pilotto A, Mergy J, Bellarbre F, Ingrand P, Paccalin M; MPI_AGE Project Investigators. Using a multidimensional prognostic index (MPI) based on comprehensive geriatric assessment (CGA) to predict mortality in elderly undergoing transcatheter aortic valve implantation. *Int J Cardiol.* 2017 Jun 1;236:381-386.
174. Rea F, Bonassi S, Vitale C, Trifirò G, Cascini S, Roberto G, Chinellato A, Lucenteforte E, Mugelli A, Corrao G; I-GrADE investigators. Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: Evidence from the AIFA - I-GrADE observational project. *Pharmacoepidemiol Drug Saf.* 2017 Jul;26(7):775-784.
175. Ferrara R, Ientile V, Arcoraci V, Ferrajolo C, Piccinni C, Fontana A, Benvenga S, Trifirò G. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015. *Endocrine.* 2017 Oct;58(1):143-152.
176. Ferrajolo C, Verhamme KM, Trifirò G, 't Jong GW, Picelli G, Giaquinto C, Mazzaglia G, Stricker BH, Rossi F, Capuano A, Sturkenboom MC. Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. *Drug Saf.* 2017 Apr;40(4):305-315.
177. Youngster I, Avorn J, Belleudi V, Cantarutti A4, Díez-Domingo J, Kirchmayer U, Park BJ, Peiró S, Sanfèlix-Gimeno G, Schröder H, Schüssel K, Shin JY, Shin SM, Simonsen GS, Blix HS, Tong A, Trifirò G, Ziv-Baran T, Kim SC. Antibiotic use in children - a cross-national analysis of 6 countries. *J Pediatr.* 2017 Mar;182:239-244.e1.
178. Trifirò G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Frøslev T, Molokhia M, Diemberger I, Sturkenboom MCJM. Association of azithromycin and ventricular arrhythmia: a European multi-database, population-based study. *CMAJ.* 2017 Apr 18;189(15):E560-E568.
179. Vetrano DL, La Carpia D, Grande G, Casucci P, Bacelli T, Bernabei R, Onder G; Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic Medication Burden and 5-Year Risk of Hospitalization and Death in Nursing Home Elderly Residents With Coronary Artery Disease. *J Am Med Dir Assoc.* 2016 Nov 1;17(11):1056-1059.
180. Pilotto A, Gallina P, Panza F, Copetti M, Cella A, Cruz-Jentoft A, Daragjati J, Ferrucci L, Maggi S, Mattace-Raso F, Paccalin M, Polidori MC, Topinkova E, Trifirò G, Welmer AK, Strandberg T, and Marchionni N, the MPI_AGE Project Investigators. Relation of Statin Use and Mortality in Community-dwelling Frail Older Patients with Coronary Artery Disease. *Am J Cardiol.* 2016 Dec 1;118(11):1624-1630.

181. Viola E, Trifirò G, Ingrassiotta Y, Sottosanti L, Tari M, Giorgianni F, Moretti U, Leone R. Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study. *Expert Opin Drug Saf.* 2016 Dec;15(sup2):61-67.
182. Sultana J, Fontana A, Giorgianni F, Pasqua A, Cricelli C, Spina E, Gambassi G, Ivanovic J, Ferrajolo C, Molokhia M, Ballard C, Sharpi S, Sturkenboom M, Trifirò G. The effect of safety warnings on antipsychotic drug prescribing in elderly persons with dementia in the United Kingdom and Italy: a population-based study. *CNS Drugs.* 2016 Nov;30(11):1097-1109.
183. Pilotto A, Gallina P, Copetti M, Pilotto A, Marcato F, Mello AM, Simonato M, Logroscino G, Padovani A, Ferrucci L, Panza F; Multidimensional Prognostic Index_Age Project Investigators. Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. *J Am Geriatr Soc.* 2016 Jul;64(7):1416-24.
184. Ingrassiotta I, Giorgianni F, Marciàno I, Bolcato J, Pirolo R, Chinellato A, Ientile V, Santoro D, Genazzani AA, Alibrandi A, Fontana A, Caputi AP, Trifirò G. Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: an Italian population-based study. *PLoS One.* 2016 May 17;11(5):e0155805.
185. Guerriero F, Orlando V, Tari DU, Di Giorgio A, Cittadini A, Trifirò G, Menditto E. How healthy is community-dwelling elderly population? Results from Southern Italy. *Transl Med UniSa.* 2016 Jan 31;13:59-64.
186. Marciàno I, Ingrassiotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Di Giorgio A, Manna S, Ientile V, Gini R, Santarpia M, Genazzani AA, Uomo I, Pastorello M, Pollina Addario WS, Scondotto S, Cananzi P, Da Cas R, Traversa G, Rossi M, Sottosanti L, Caputi AP, Trifirò G. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009-2014. *BioDrugs.* 2016 Aug;30(4):295-306.
187. Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Pilgaard Ulrichsen S, Pedersen L, Poluzzi E, De Ponti F, Garbe E, Schink T, Herings R, Bezemer I, Sturkenboom MCJM, Trifirò G. Prescribing pattern of antipsychotic drugs with torsadogenic liability during the years 1996-2010: a population-based database study in Europe. *Br J Clin Pharmacol.* 2016 Aug;82(2):487-97.
188. Ferrara R, Arcoraci V, Trifirò G. Critical issues of inhaled corticosteroids (ICS) use in chronic obstructive pulmonary disease (COPD) patients. *Journal of Respiratory Research.* Vol 2, No 1 (2016).
189. Sultana J, Leal I, De Ridder M, Sturkenboom M, **Trifirò G.** Antipsychotic use in dementia patients in a general practice setting: a Dutch population-based study. *Epidemiol Psychiatr Sci.* 2016 Aug;25(4):403-6.
190. Pizzimenti V, Giandalia A, Cucinotta D, Russo GT, Smits M, Cutroneo PM, Trifirò G. Incretin-Based Therapy and Acute Cholecystitis: a Review of Case Reports and Eudravigilance Spontaneous Adverse Drug Reaction Reporting Database. *J Clin Pharm Ther.* 2016 Apr;41(2):116-8.
191. Gini R, Schuemie M, Brown J, Ryan P, Vacchi E, Coppola M, Cazzola W, Coloma P, Berni R, Diallo G, Oliveira JL, Avillach P, Trifirò G, Rijnbeek P, Bellentani M, van Der Lei J, Klazinga N, and Sturkenboom M. Data Extraction And Management In Networks Of Observational Health Care Databases For Scientific Research: A Comparison Among EU-ADR, OMOP, Mini-Sentinel And MATRICE Strategies. Generating Evidence & Methods to improve patient outcomes. *EGEMS (Wash DC).* 2016 Feb 8;4(1):1189.
192. Trifirò G, Sultana J, Parrino F, Tari DU, Fontana A, Giorgianni F, Ferrajolo C, Troncone C, Ientile V, Caputi AP. The impact of antidepressant treatment adherence on the use of diagnostic radiology and laboratory tests in patients with depressive/anxiety disorders: a population-based study. *International Journal of Community & Family Medicine* Volume 1 (2016), Article ID 1:IJCFM-101, 6 pages.

193. Sultana J, Basile G, Trifirò G. Measuring frailty in population-based healthcare databases: Multi-dimensional prognostic indices for the improvement of geriatric care. *Geriatric Care* 2016, 2(1). <https://doi.org/10.4081/gc.2016.5596>.
194. Coloma P, de Ridder M, Bezemer I, Herings R, Gini R, Pecchioli S, Scotti L, Rijnbeek P, Mosseveld M, van der Lei J, Trifirò G and Sturkenboom M. Risk of Cardiac Valvulopathy With Use of Bisphosphonates: a Population-Based, Multi-Country Case-Control Study. *Osteoporos Int.* 2016 May;27(5):1857-67.
195. Trifirò G; Parrino F; Pizzimenti V; Giorgianni F; Sultana J; Muscianisi M; Troncone C; Tari DU; Arcoraci V; Santoro D; Russo G; Lacava V; Caputi AP. The management of type II diabetes in patients with chronic kidney disease: a population-based study in Southern Italy. *Clin Drug Investig.* 2016 Mar;36(3):203-12.
196. Bezemer I, Verhamme K, Gini R, Mosseveld M, Rijnbeek P, Trifirò G, Sturkenboom MCJM, Penning-van Beest FJA, and Herings R. Use of oral contraceptives in three European countries: a population-based multi-database study. *Eur J Contracept Reprod Health Care.* 2016;21(1):81-7.
197. Pilotto A, Panza F, Copetti M, Simonato M, Sancarlo D, Gallina P, Strandberg T; MPI_AGE Project Investigators. Statin Treatment and Mortality in Community-Dwelling Frail Older Patients with Diabetes Mellitus: A Retrospective Observational Study. *PLoS One.* 2015 Jun 25;10(6):e0130946.
198. Santoro D, Savica V and **Trifirò G**. Absorbable phosphate in medication. *Kidney Int.* 2016 Mar;89(3):721.
199. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, **Trifirò G**. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013. *BioDrugs.* 2015 Aug;29(4):275-84.
200. Pacurariu AC, Straus SM, **Trifirò G**, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma P. Useful interplay between spontaneous ADR reports and electronic healthcare records as sources of safety signals. *Drug Saf.* 2015 Dec;38(12):1201-10.
201. Sultana J, Musazzi UM, Ingrasciotta Y, Giorgianni F, Ientile V, Fontana A, Minghetti P, Perrotta M, Santoro D, Savica V, **Trifirò G**. Medication is an additional source of phosphate intake in chronic kidney disease patients. *Nutr Metab Cardiovasc Dis.* 2015 Oct;25(10):959-67.
202. Santoro D, Pellicanò V, Visconti L, **Trifirò G**, Buemi M, Cernaro V. An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease. *Expert Opin Investig Drugs.* 2015 Jun 30:1-20.
203. Lapi F, Bianchini E, Cricelli I, Mazzaglia G, **Trifirò G**, Cricelli C. Development and validation of a score for adjusting healthcare costs in general practice. *Value Health.* 2015 Sep;18(6):884-95.
204. Holstiege J, Enders D, Schink T, Innocenti F, Oteri A, Bezemer I, Kaguelidou F, Molokhia M, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MC, **Trifirò G**, Garbe E. Trends in paediatric macrolide use in five European countries – a population-based study. *European Journal of Clinical Pharmacology* 2015 Aug;71(8):991-9.
205. Nosè M, Recla E, **Trifirò G**, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. *Pharmacoepidemiol Drug Saf.* 2015 Aug;24(8):812-20.
206. Polimeni G, **Trifirò G**, Ingrasciotta Y, Caputi AP. The advent of biosimilars for the treatment of diabetes: current status and future directions. *Acta Diabetol.* 2015 Jun;52(3):423-31.
207. Santoro D, Pellicanò V, Visconti L, **Trifirò G**, Cernaro V, Buemi M. Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. *Expert Opin Biol Ther.* 2015 Jun 19:1-25.
208. Mor A, Frøslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, Garbe E, Pecchioli S, Innocenti F, Bezemer I, Poluzzi E, Sturkenboom

- MC, **Trifirò G**, Søgaaard M. Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. *Infection*. 2015 Aug;43(4):453-72.
209. Ingrasciotta Y, Sultana J, Giorgianni F, Fontana A, Santangelo A, Tari DU, Santoro D, Arcoraci V, Perrotta M, Ibanez L, **Trifirò G**. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. *PLoS One*. 2015 Apr 16;10(4):e0122899.
 210. Sultana J, Spina E, **Trifirò G**. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. *Expert Opin Drug Metab Toxicol*. 2015 Jun;11(6):883-92.
 211. de Bie S, Coloma P, Ferrajolo C, Verhamme K, **Trifirò G**, Schuemie M, Straus S, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker B, van der Lei J, Sturkenboom M. The Role of Electronic Healthcare Record Databases in Paediatric Drug Safety Surveillance: a Retrospective Cohort Study. *Br J Clin Pharmacol*. 2015 Aug;80(2):304-14.
 212. **Trifirò G**, Parrino F, Sultana J, Giorgianni F, Ferrajolo C, Bianchini E, Medea G, Benvenga S, Cricelli I, Cricelli C, Lapi F. Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice. *Clin Drug Investig*. 2015 Mar;35(3):187-95.
 213. Rafaniello C, Arcoraci V, Ferrajolo C, Sportiello L, Sullo MG, Giorgianni F, **Trifirò G**, Tari M, Caputi AP, Rossi F, Esposito K, Giugliano D, Capuano A. Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study. *Diabetes Res Clin Pract*. 2015 Apr;108(1):157-63.
 214. Herrera L, Leal I, Lapi F, Schuemie M, Arcoraci V, Cipriani F, Sessa E, Vaccheri A, Piccinni C, Staniscia T, Vestri A, Di Bari M, Corrao G, Zambon A, Gregori D, Carle F, Sturkenboom M, Mazzaglia G, **Trifirò G**. Risk of atrial fibrillation among bisphosphonates users: a multi-center, population-based, Italian study. *Osteoporos Int*. 2015 May;26(5):1499-506.
 215. Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A, **Trifirò G**, Sultana J, Ferrajolo C, Tari M, Tari DU, Perrotta M, Pagliaro C, Rossi F, Caputi AP, Spina E, Arcoraci V. Indications of Newer And Older Antiepileptic Drug Use: Findings From A Southern Italian General Practice Setting From 2005—2011. *Br J Clin Pharmacol*. 2015 Jun;79(6):1010-9.
 216. Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, Sturkenboom M, **Trifirò G**, on behalf of the EU-ADR consortium. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. *Int J Clin Pharm*. 2015 Feb;37(1):94-104.
 217. Patadia VK, Coloma P, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Fornari C, Pedersen L, van der Lei J, Straus S, Sturkenboom M, **Trifirò G**, on behalf of the EU-ADR consortium. Using Real-World Healthcare Data for Pharmacovigilance Signal Detection - the Experience of the EU-ADR Project. *Expert Rev Clin Pharmacol*. 2015 Jan;8(1):95-102.
 218. Sultana J, Parrino F and **Trifirò G**. Prescribing Generic or Branded Antidepressants: What to Choose? *Ann Depress Anxiety* 2014;1(6): 1028.
 219. Sultana J and **Trifirò G**. Drug Safety Warnings: A Message in a Bottle. *J Drug Des Res* 2014; 1(1): 1004.
 220. **Trifirò G**, Sultana J, Gambassi G. Antipsychotic use in elderly patients and the risk of pneumonia. *Expert Opin Drug Saf*. 2015 Jan;14(1):1-6.
 221. Bellinghieri G, Condemi CG, Saitta S, Trifirò G, Gangemi S, Savica V, Buemi M, Santoro D. Erythropoiesis- Stimulating Agents: Dose and Mortality Risk. *J Ren Nutr*. 2015 Mar;25(2):164-8.
 222. **Trifirò G**, Sultana J, Giorgianni F, Ingrassiotta Y, Muscianisi M, Tari DU, Perrotta M, Canale V, Arcoraci V, Santoro D. Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. *Biomed Res Int*. 2014;2014:268362.
 223. Italiano D, Bianchini E, Iardi M, Cilia R, Pezzoli G, Zanettini R, Vacca L, Stocchi F, Bramanti P, Ciurleo R, Di Lorenzo G, Polimeni G, de Luise C, Ross D, Rijnbeek P, Sturkenboom M, **Trifirò G**. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. *J Neural Transm*. 2015 Jun;122(6):799-808.

224. Cutroneo PM, Isgrò V, Russo A, Ientile V, Sottosanti L, Pimpinella G, Conforti A, Moretti U, Caputi AP, **Trifirò G**. Safety profile of biological medicines as compared to non-biologicals: an Analysis of Italian Spontaneous Reporting System Database. *Drug Saf.* 2014 Nov;37(11):961-70.
225. **Trifirò G**, Fatuzzo PM, Ientile V, Pizzimenti V, Ferrajolo C, Santoro D, Camacho N, Van Rosmalen J, D'Addetta G, Lanati P, Caputi AP, Catinello G, Savica V. Expert opinion of nephrologists about the effectiveness of low protein diet in different stages of Chronic Kidney Disease (CKD). *Int J Food Sci Nutr.* 2014 Dec;65(8):1027-32.
226. Boyce RD, Ryan PB, Norén GN, Schuemie MJ, Reich C, Duke J, Tatonetti NP, **Trifirò G**, Harpaz R, Overhage JM, Hartzema AG, Khayter M, Voss EA, Lambert CG, Huser V, Dumontier M. Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. *Drug Saf.* 2014 Aug;37(8):557-67.
227. Holstiege JB, Schink T, Molokhia M, Mazzaglia G, Innocenti F, Oteri A, Bezemer I, Poluzzi E, Puccini A, Pilgaard Ulrichsen S, Sturkenboom MC, **Trifirò G** and Garbe E. Systemic antibiotic prescribing to pediatric outpatients in 5 European countries: a population-based cohort study. *BMC Pediatr.* 2014 Jul 5;14:174.
228. Mazzaglia G, Piccinni C, Filippi A, Sini G, Lapi F, Sessa E, Cricelli I, Cutroneo P, **Trifirò G**, Cricelli C, Caputi AP. Effects of a computerized decision support system in improving pharmacological management in high-risk cardiovascular patients: a cluster-randomized open-label controlled trial. *Health Informatics J.* 2016 Jun;22(2):232-47.
229. Ferrajolo C, Capuano A, **Trifirò G**, Moretti U, Rossi F, Santuccio C. Paediatric Drug Safety Surveillance in Italian Pharmacovigilance Network: an Overview of Adverse Drug Reactions in the years 2001-2012. *Expert Opin Drug Saf.* 2014 Sep;13 Suppl 1:S9-20.
230. Ferrajolo C, Arcoraci A, **Trifirò G**, Tari M, Sportiello L, Sullo P, Rafaniello C, Caputi AP, Agliaro C, Capuano A, Rossi F. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?. *PLoS One.* 2014 Jul 29;9(7):e102146.
231. **Trifirò G**, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. *Drug Saf.* 2014 Jul;37(7):501-20.
232. Schuemie M, **Trifirò G**, Coloma P, Ryan P, Madigan D. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The Exposure-adjusted Self-Controlled Case Series. *Stat Methods Med Res.* 2016 Dec;25(6):2577-2592.
233. Basile G, Epifanio A, Mandraffino R, Trifirò G. Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions. *J Clin Pharm Ther.* 2014 Aug;39(4):452-4.
234. Valkhoff V, Coloma P, Masclee G, Gini R, Innocenti F, Lapi F, Molokhia M, Mosseveld M, Schou Nielsson M, Schuemie M, Thiessard F, van der Lei J, Sturkenboom M, **Trifirò G**, on behalf of the EU-ADR Consortium. Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. *Journal of Clinical Epidemiology. J Clin Epidemiol.* 2014 Aug;67(8):921-31.
235. Cernaro V, **Trifirò G**, Lorenzano G, Lucisano S, Buemi M, Santoro D. New therapeutic strategies under development to halt the progression of renal failure. *Expert Opin Investig Drugs.* 2014 May;23(5):693-709.
236. Ingrassiotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, Linguiti C, Perrotta M, Nucita A, Pellegrini F, Fontana A, Cavagna L, Santoro D, **Trifirò G**. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. *PLoS One.* 2014 Feb 18;9(2):e89072.
237. Sultana J, Italiano D, Spina E, Cricelli C, Lapi F, Pecchioli S, Gambassi G, **Trifirò G**. Changes in the prescription pattern of antidepressant drugs in elderly patients: an Italian, nationwide population-based study. *Eur J Clin Pharmacol.* 2014 Apr;70(4):469-78.
238. Ferrajolo C, Coloma P, Verhamme KMC, Schuemie M, de Bie S, Gini R, Herings R, Mazzaglia G, Picelli G, Giaquinto C, Scotti L, Avillach P,

- Pedersen L, Rossi F, Capuano A, van der Lei J, **Trifirò G**, and Sturkenboom M.C.J.M., on behalf of EU-ADR consortium. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. *Drug Saf*. 2014; 37:99-108.
239. **Trifirò G**, P. Coloma, P. Rijnbeek, S. Romio, B. Mosseveld, D. Weibel, J. Bonhoeffer, M. Schuemie, J. van der Lei, and M. Sturkenboom. Combining multiple healthcare databases for post-marketing drug and vaccine safety surveillance: why and how? *J Intern Med*. 2014 Jun;275(6):551-61.
 240. Coloma P, Schuemie M, **Trifirò G**, Furlong L, van Mulligen E, Bauer-Mehren A, Avillach P, Kors J, Sanz F, Mestres J, Luis Oliveira J, Boyer S, Ahlberg Helgee E, Molokhia M, Matthews J, Prieto-Merino D, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, van der Lei J, Sturkenboom M on behalf of the EU-ADR consortium. Drug-induced Acute Myocardial Infarction: Identifying 'Prime Suspects' from Electronic Healthcare Records-based Surveillance System. *Plos One* 2013 Aug; 8:e72148.
 241. Sultana J, Cutroneo P and **Trifirò G**. Clinical and economic burden of adverse drug reactions. *J Pharmacol Pharmacother* 2013 Dec; 4: S73-S77.
 242. Sterrantino C, **Trifirò G***, Lapi F, Pasqua A, Mazzaglia G, Piccinni C, Cricelli C, Rossi A, Blasi F. Burden of Community-Acquired Pneumonia in Italian General Practice. *Eur Resp J* 2013 Dec; 42: 1739-42.
 243. Zomerdijk IM, **Trifirò G**, Sayed-Tabatabaei FA, Sturkenboom M and Straus S. Additional risk minimisation measures in the EU– are they eligible for assessment? *Pharmacoepidemiology and Drug Saf* 2013 Oct; 22: 1046-53.
 244. Onder G, Bonassi S, Abbatecola A, Folino-Gallo P, Lapi F, Marchionni N, Pani L, Rasi G, Sancarlo D, Scuteri A, **Trifirò G**, Vitale C, Bernabei R, Fini M on behalf of the Geriatrics Working Group of the Italian Medicines Agency (AIFA). High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA). *J Gerontol A Biol Sci Med Sci* . 2014 Apr;69(4):430-7.
 245. **Trifirò G**, Italiano D, Alibrandi A, Sini G, Tari M, Linguiti C, Ferrajolo C, Capuano A, Spina E, Stratta P, Allegrini F, Rossi A. Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. *Int J Clin Pharm*. 2013 Dec; 35:1053-62.
 246. Coloma P, Valkhoff V, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M, Mosseveld M, Morabito P, Schuemie M, Sturkenboom M, **Trifirò G**, on behalf of the EU-ADR Consortium. Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. *BMJ Open*. 2013 Jun 20; 3(6).
 247. Masclee GM, Valkhoff VE, van Soest EM, Schade R, Mazzaglia G, Molokhia M, **Trifirò G**, Goldstein JL, Hernández-Díaz S, Kuipers EJ, Sturkenboom MC. Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? *Aliment Pharmacol Ther*. 2013 Jul;38(2):178-89.
 248. Cavagna L, Caporali R, **Trifirò G**, Arcoraci V, Rossi S, Montecucco C. Overuse of prescription and otc non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. *Int J Immunopathol Pharmacol*. 2013;26:279-81.
 249. Ferrajolo C, Verhamme K, Trifirò G, 't Jong G, Giaquinto C, Picelli G, Oteri A, de Bie S, Valkhoff V, Schuemie M, Mazzaglia G, Cricelli C, Rossi F, Capuano A, and Sturkenboom M. Idio pathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries. *Drug Saf* 2013 Oct. 36: 1007-16.
 250. Ruiter R, Visser LE, Rodenburg EM, **Trifirò G**, Ziere G, Stricker BH. ADR-related hospitalization in persons aged 55 years and older in the Netherlands. *Ned Tijdschr Geneesk*. 2013;157(6):A5182.
 251. Cutroneo P, Italiano D, **Trifirò G**, Tortorella G, Russo A, Isola S, Caputi AP, Spina E. Acute cerebellar ataxia following meningococcal group C conjugate vaccination. *J Child Neurol*. 2014 Jan; 29: 128-30.
 252. Molokhia M, De Ponti F, Behr ER, **Trifirò G**, and Sturkenboom M on behalf of the ARITMO consortium. EU funded outputs should include

- impact on regulatory decision making and policy. *Lancet*. 2012 Dec 1;380(9857):1903-4.
253. Avillach P, Dufour JC, Diallo G, Salvo F, Joubert M, Thiessard F, Mougín F, **Trifirò G**, Fourier-Réglat A, Pariente A, Fieschi M. Design and Validation of an Automated Method to Detect Known Adverse Drug Reactions in MEDLINE: a Contribution from the EU-ADR Project. *JAMIA*. 2013 May; 20: 446-52.
 254. Amr M, Amin TT, Al-Raddad D, El-Mogy A, **Trifirò G**. Antipsychotic polypharmacy among Arab patients with schizophrenia. *Arab Journal of Psychiatry* 2012;23: 115-122.
 255. Avillach P, Coloma P, Gini R, Schuemie M, Mougín F, Dufour JC, Mazzaglia G, Giaquinto C, Fornari C, Herings R, Molokhia M, Pedersen L, Fourier-Réglat A, Fieschi M, Sturkenboom M, van der Lei J, Pariente A, and **Trifirò G**, on behalf of the EU-ADR consortium. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. *J Am Med Inform Assoc*. 2013 Jan 1;20(1):184-92
 256. Coloma P, Avillach P, Schuemie M, Ferrajolo C, Pariente A, Salvo F, Fourier-Réglat A, Patadia V, Ottosson A, Molokhia M, van der Lei J, Sturkenboom M, and **Trifirò G**. A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection using Electronic Healthcare Records (EHR) Databases. *Drug Saf*. 2013 Jan;36(1):13-23.
 257. Leal I., Romio S., Oteri A., Schuemie M., Sturkenboom M., **Trifirò G**. Prescribing pattern of glucose lowering drugs in The United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. *Br J Clin Pharmacol*. 2013 Mar;75(3):861-8.
 258. Coloma P, **Trifirò G**, Patadia V and Sturkenboom M. Post-marketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? *Drug Saf*. 2013 Mar; 36:183-97.
 259. **Trifirò G**, Tillati S, Spina E, Ferrajolo C, Alacqua M, Aguglia E, Rizzi L, Caputi AP, Cricelli C and Samani F. A Nationwide Prospective study on Prescribing Pattern of Antidepressant Drugs in Italian Primary Care. *Eur J Clin Pharmacol*. 2013 Feb;69(2):227-36.
 260. **Trifirò G**, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea G, Cricelli C, Caputi AP, Mazzaglia G. Epidemiology of gout and hyperuricemia in Italy during the years 2005-2009: a nationwide, population-based study. *Ann Rheum Dis*. 2013 May; 72:694-700.
 261. Schuemie M, Coloma P, Straatman H, Herings R, **Trifirò G**, Matthews J, Prieto-Merino D, Molokhia M, Pedersen L, Gini R, Innocenti F, Mazzaglia G, Picelli G, Scotti L, van der Lei J, Sturkenboom M. Using electronic healthcare records for drug safety signal detection: a comparative evaluation of statistical methods. *Med Care*. 2012 Oct;50(10):890-7.
 262. van Mulligen E, Fourier-Réglat A, Gurwitz D, Molokhia M, Nieto A, **Trifirò G**, Kors JA, Furlong LI. EU-ADR Corpus: Annotated Drugs, Diseases, Targets, and their Relationships. *J Biomed Inform*. 2012 Oct;45(5):879-84.
 263. Valkhoff V, van Soest E, Dieleman J, Mazzaglia G, Molokhia M, Schade R, **Trifirò G**, Goldstein JL, Hernandez-Diaz S, Kuipers EJ, Sturkenboom M. Adherence to gastroprotection in addition to cyclooxygenase-2 inhibitor and the risk of upper gastrointestinal events: a population-based study using three European databases. *Arthritis Rheum*. 2012 Aug;64(8):2792-802.
 264. Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V, Cananzi P, Savica V, Schuemie M, Caputi AP, **Trifirò G**. How much are biosimilars used in Southern Italy? A retrospective analysis of epoetin utilization in the Local Health Unit of Messina in the years 2010–2011. *BioDrugs*. 2012 Apr 1;26(2):113-20.
 265. Ruiter R, Visser LE, Rodenburg EM, **Trifirò G**, Ziere G, Stricker BHCh. Trends in adverse drug reaction related hospitalizations in persons aged 55 years and over: a population based study in the Netherlands. *Drugs Aging*. 2012 Mar 1;29(3):225-32.
 266. Coloma PM, **Trifirò G**, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, van der Lei J, and Sturkenboom MCJM on behalf of the EU-ADR consortium. Electronic

- healthcare databases for active drug safety surveillance: Is there enough leverage? *Pharmacoepidemiol Drug Saf.* 2012 Jun;21(6):611-621
267. Mokhles MM*, **Trifirò G***, Dieleman JP, Haag M, van Soest E, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC.J.M. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. *Pharmacol Res.* 2012 Mar;65(3):358-64
 268. Spina E, **Trifirò G**, Caraci F. Clinically significant drug interactions with newer antidepressants. *CNS drugs.* 2012 Jan 1;26(1):39-67.
 269. Zomerdijk I, Sayed-Tabatabaei FA, **Trifirò G**, Blackburn S, Sturkenboom M, Straus S. Risk Minimisation Activities of Centrally Authorised Products in the European Union: A descriptive study. *Drug Saf.* 2012 Apr 1;35(4):299-314.
 270. **Trifirò G**, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinemia: a multi-country, nested case control study. *Drug Saf.* 2012 Feb 1;35(2):159-71
 271. van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, Hernández-Díaz S, **Trifirò G**, Dieleman JP, Kuipers EJ, Sturkenboom MC. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. *Gut.* 2011 Dec;60(12):1650-9
 272. **Trifirò G**, Spina E. Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems. *Curr Drug Metab.* 2011 Sep;12(7):611-20.
 273. **Trifirò G**, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Scotti L, Pedersen L, Avillach P, Sturkenboom MCJM, and van der Lei J on behalf of the EU-ADR Group. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. *Stud Health Technol Inform.* 2011;166:25-30.
 274. **Trifirò G**. Antipsychotic Drug Use and Community-Acquired Pneumonia. *Current Infectious Disease Reports.* *Curr Infect Dis Rep.* 2011 Jun;13(3):262-8.
 275. Avillach P, Joubert M, Thiessard F, **Trifirò G**, Dufour JC, Pariente A, Mougín F, Polimeni G, Catania MA, Giaquinto C, Mazzaglia G, Fornari C, Herings R, Gini R, Hippisley-Cox J, Molokhia M, Pedersen L, Fourier-Réglat A, Sturkenboom M, Fieschi M. Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project. *Stud Health Technol Inform.* 2010;160(Pt 2):1085-9.
 276. Coloma P, Schuemie M, **Trifirò G**, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, and Sturkenboom M, on behalf of the EU-ADR consortium. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. *Pharmacoepidemiol Drug Saf* 2011; 20(1):1-11
 277. Oteri A, **Trifirò G**, Gagliostro MS, Tari DU, Moretti S, Bramanti P, Spina E, Caputi AP, Arcoraci V. Use of antiepileptic drugs in elderly outpatient of Southern Italy during the years 2004-2007: the effect of health policy intervention. *Br J Clin Pharmacol.* 2010 Oct;70(4):514-22.
 278. **Trifirò G**, Dieleman J, Sen EF, Gambassi G, Sturkenboom MC. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. *J Clin Psychopharmacol.* 2010 Jun; 30:252-8.
 279. **Trifirò G**, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. *Ann Intern Med.* 2010 Apr 6;152(7):418-25, W139-40.
 280. **Trifirò G**, Sini G, Sturkenboom MC, Vanacore N, Mazzaglia G, Caputi AP, Cricelli C, Brignoli O, Aguglia E, Biggio G, Samani F. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005:

- a focus on elderly with dementia. *Int Clin Psychopharmacol.* 2010; 25:22-8.
281. Savica R, Granata F, La Spina P, Pitrone A, Calabrò R.S., Postorino P, **Trifirò G**, Longo M, Musolino R. Cerebellar stroke in elderly patient with Basilar Artery Agenesis: a case report. *J Stroke Cerebrovasc Dis.* 2010 Jan;19(1):81-3.
 282. Alacqua M, **Trifirò G**, Spina E, Moretti S, Tari DU, Bramanti P, Caputi AP, and Arcoraci V. Newer and older antiepileptic drug use in Southern Italy: a population based study during the years 2003-2005. *Epilepsy Res.* 2009 Jul;85(1):107-13.
 283. **Trifirò G**, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? *Pharmacol Res.* 2009;59:1-12. Review.
 284. Polimeni G, Russo A, Catania MA, Aiello A, Oteri A, **Trifirò G**, Calapai G, Sautebin L, Iacobelli M, Caputi AP. Drug safety information through the internet: the experience of an Italian website. *Drug Saf.* 2009;32(3):245-53.
 285. Avillach P, Mouglin F, Joubert M, Thiessard F, Pariente A, Dufour JC, **Trifirò G**, Polimeni G, Catania MA, Giaquinto C, Mazzaglia G, Baio G, Herings R, Gini R, Hippisley-Cox J, Molokhia M, Pedersen L, Fourier-Réglat A, Sturkenboom M, Fieschi M. A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project. *Stud Health Technol Inform.* 2009;150:190-4.
 286. **Trifirò G**, Fourier-Réglat A, Sturkenboom MC, Díaz Acedo C, Van Der Lei J; EU-ADR Group. The EU-ADR project: preliminary results and perspective. *Stud Health Technol Inform.* 2009;148:43-9.
 287. **Trifirò G**, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, Catania MA, Salvo F, David A, Moore N, Caputi AP, Sturkenboom M, Molokhia M, Hippisley-Cox J, Acedo CD, van der Lei J, Fourier-Réglat A; EU-ADR group. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? *Pharmacoepidemiol Drug Saf.* 2009; 18:1176-84.
 288. Alacqua M, **Trifirò G**, Cavagna L, Caporali R, Montecucco CM, Moretti S, Tari DU, Galdo M, Caputi AP, Arcoraci V. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: The effect of rofecoxib withdrawal. *Arthritis care and research.* 2008; 59:568-574.
 289. Mazzaglia G, Yurgin N, Boye KS, **Trifirò G**, Cottrell S, Allen E, Filippi A, Medea G, Cricelli C. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a four year descriptive study from national primary care data. *Pharmacol Res.* 2008 May;57(5):358-63.
 290. **Trifirò G**, Savica R, Morgante L, Vanacore N, Tari M, Moretti S, Galdo M, Spina E, Caputi AP, UVEC group and Arcoraci V. Prescribing pattern of Anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-5. *Parkinsonism Relat Disord.* 2008;14(5):420-5.
 291. **Trifirò G**, Morgante L, Tari M, Arcoraci V, Savica R. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent. *J Am Geriatr Soc.* 2008; 56:371-3.
 292. **Trifirò G**, Alacqua M, Corrao S, Moretti S, Tari DU, Galdo M; UVEC Group, Caputi AP, Arcoraci V. Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision. *Eur J Clin Pharmacol.* 2008 Jun;64(6):619-25.
 293. **Trifirò G**, Alacqua M, Corrao S, Tari M, Arcoraci V. Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials. *J Am Geriatr Soc.* 2008; 56:175-7.
 294. Alacqua M, **Trifirò G**, Arcoraci V, Germanò E, Magazù A, Calarese T, Di Vita G, Gagliano C, Spina E. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. *Pharm World Sci.* 2008; 30:44-50.
 295. Sacchetti E, **Trifirò G**, Caputi A, Turrina C, Spina E, Cricelli C, Brignoli O, Sessa E, Mazzaglia G. Risk of stroke with typical and atypical antipsychotics: a retrospective cohort study including unexposed subjects. *J Psychopharmacol.* 2008;22:39-46.
 296. **Trifirò G**, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, Caputi AP, Arcoraci V and UVEC group. Antidepressant drugs: prevalence, incidence

- and indication of use in general practice of Southern Italy during the years 2003-2004. *Pharmacoepidemiol Drug Saf.* 2007; 16:552-9.
297. **Trifirò G**, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. *Pharmacoepidemiol Drug Saf.* 2007; 16:538-44.
 298. Spina E and **Trifirò G**. Preventing drug interactions with antidepressants in the elderly. *Aging Health* 2007; 3(2): 231-243. Review.
 299. Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, Caputi AP, Musolino R, Spina E, **Trifirò G**. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. *Eur J Neurol.* 2007; 14:1317-21.
 300. **Trifirò G**, Spina E, Savica R, Beghi E, Innocenti F, Mazzaglia G, Brignoli O, Cricelli C, Caputi AP. Prescribing pattern of anti-epileptic drugs in Italy: a population-based study. *Proceedings 8th Congress of the EACPT. Monduzzi Editore*, pp. 43-46, 2007.
 301. **Trifirò G**, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP, Arcoraci V; UVEC Group. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. *Br J Clin Pharmacol* 2006; 62:582-90.
 302. **Trifirò G**. Drug-drug interactions and statin therapy. *South Med J* 2006; 99:1325-6. Editorial.
 303. Filippi A, Sessa E, Pecchioli S, **Trifirò G**, Samani F, Mazzaglia G. Homecare for patients with heart failure in Italy. *Ital Heart J.* 2005 Jul;6(7):573-7.
 304. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, **Trifirò G**, Cricelli C, Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. *J Hypertens.* 2005 Nov;23(11):2093-100.
 305. Piacentini N, **Trifirò G**, Tari M, Moretti S, UVEC group, Arcoraci V. Statin-macrolide interaction risk: a population-based study throughout a general practice database. *Eur J Clin Pharmacol.* 2005 Sep;61(8):615-20.
 306. **Trifirò G**, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during 1999-2002 years. *Eur J Clin Pharmacol.* 2005 Mar;61(1):47-53.
 307. **Trifirò G**, Calogero G, Menniti Ippolito F, Cosentino M, Giuliani R, Conforti A, Venegoni M, Mazzaglia G, Caputi AP. Adverse drug events in emergency department population: a prospective Italian study. *Pharmacoepidemiol Drug Saf.* 2005 May;14(5):333-40.
 308. Filippi A, Sessa E, **Trifirò G**, Mazzaglia G, Pecchioli S, Caputi AP, Cricelli C. Oral anticoagulant therapy in Italy: prescribing prevalence and clinical reasons. *Pharmacol Res.* 2004 Dec;50(6):601-3.

Books

- G. Trifirò and E. Spina - Authors of the book "Pharmacovigilance in Psychiatry" – Springer.
- G. Trifirò and P. Coloma. Leveraging routinely collected healthcare data to scale up drug safety surveillance: the EU-ADR experience, chapter of the book "Pharmacovigilance" 3rd Edition, R. Mann, E. Andrews and N. Moore, Wiley editor.
- Bate A, Trifirò G, Avillach P and Evans S. Data Mining and Other Informatics Approaches to Pharmacoepidemiology, chapter of the book *Pharmacoepidemiology*, V edition, edited by Wiley-Blackwell.
- Horton DB, Bhullar H, Carty L, Cunningham F, Ogdie-Beatty A, Sultana J, Trifirò G. Electronic Health Record Databases – chapter of the book *Pharmacoepidemiology*, V, VI e VII editions, edited by Wiley-Blackwell.
- G. Trifirò and HT Sorensen. Drug Utilization and Outcomes Research, chapter of the book "Drug Utilization Research", edited by Wiley.
- Trifirò G. Real World Evidence e Farmaci: applicazioni e criticità nel contesto Italiano – Seed editore.
- G. Trifirò and I. Diemberger. "Farmaci Antiaritmici", chapter of the Italian book "Farmacologia" di Govoni, edited by CEA – Casa Editrice

Ambrosiana

- Capuano A, Trifirò G and Ferrajolo C. PRINCIPI DI FARMACOEPIDEMOLOGIA - Chapter of the book Farmacologia - Principi di base e applicazioni terapeutiche di Rossi - Cuomo - Riccardi

Patency and other achievements

Development of App for android and IOS-based systems for the management of COPD patients in routine care – Società Italiana Degli Autori ed Editori - registration number n. 2016001533 – OLAF section

Participation to more than 200 international and national seminars and conferences as chairman, invited speaker or lecturer.

I hereby Gianluca Trifirò, born in Messina on the 30/01/1978 and resident in via Consolare Pompea 75, 98168 Messina authorizes the use of own personal data in agreement with the national law 675/96 concerning data privacy.

Verona, 10th March 2025

Prof. Gianluca Trifirò

